# *Ezh2 Delays Activation of Differentiation Genes During Normal Cerebellar Granule Neuron Development and in Medulloblastoma*

**Authors:** James Purzner[1,2,3*], Alexander S. Brown[3,4], Teresa Purzner[1,2,3], Lauren Ellis[3,5], Sara Broski[3,6], Ulrike Litzenburger[3,7], Kaytlin Andrews[8], Aryaman Sharma[8], Xin Wang[9,10], Michael D. Taylor[11], Yoon-Jae Cho[12,13,14], Margaret T. Fuller[3,15], and Matthew P. Scott[3*]

**Affiliations:**
[1]Division of Neurosurgery, Department of Surgery, Queen's University, Kingston, ON
[2]Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON
[3]Department of Developmental Biology, Stanford University School of Medicine, Stanford, CA
[4]EditCo Bio, Redwood City, CA
[5]Department of Anesthesiology, University of California Los Angeles, Los Angeles, CA.
[6]Nura Bio, South San Francisco, CA
[7]Therapeutic Oncology Research Lab Head, Nuvisan Pharma, Berlin, Germany
[8]Department of Medcine, Queen's University, Kingston, ON
[9]Clinician-Scientist Training Program, Temerty Faculty of Medicine, University of Toronto, Toronto, ON
[10]Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON
[11]Pediatric Brain Tumor Research Program, Texas Children's Hospital, Houston, TX
[12]Division of Pediatric Neurology, Department of Pediatrics, Oregon Health & Science University, Portland, Oregon USA
[13]Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, Oregon USA
[14]Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon USA
[15]Department of Genetics, Stanford University School of Medicine, Stanford, CA

*Correspondence to: mscott@stanford.edu, jgp12@queensu.ca

**Key Words:**
**cerebellum, cerebellar granule neuron, Ezh2, polycomb, PRC2, chromatin immunoprecipitation, transcription, brain development, differentiation, medulloblastoma**

## Abstract

Medulloblastoma (MB) is the most common malignant brain tumour in children. The Sonic Hedgehog (SHH)-medulloblastoma subtype arises from the cerebellar granule neuron lineage. Terminally differentiated neurons are incapable of undergoing further cell division, so an effective treatment for this tumour could be to force neuronal differentiation. Differentiation therapy provides a potential alternative for patients with medulloblastoma who harbor mutations that impair cell death pathways (TP53), which is associated a with high mortality. To this end, our goal was to explore epigenetic regulation of cerebellar granule neuron differentiation in medulloblastoma cells. Key regulators were discovered using chromatin immunoprecipitation with high-throughput sequencing. DNA-bound protein and chromatin protein modifications were investigated across all genes. We discovered that Ezh2-mediated tri-methylation of the H3 histone (H3K27me3), occurred on more than half of the 787 genes whose transcription normally increases as granule neurons terminally differentiate. Conditional knockout of *Ezh2* led to early initiation of differentiation in granule neuron precursors (GNPs), but only after cell cycle exit had occurred. Similarly, in MB cells, neuronal differentiation could be induced by preventing H3K27me3 modifications using an Ezh2 inhibitor (UNC1999), but only when UNC1999 was combined with forced cell cycle exit driven by a CDK4/6 inhibitor (Palbociclib). Ezh2 emerges as a powerful restraint upon post-mitotic differentiation during normal GNP development and combination of Ezh2 inhibition with cell cycle exit leads to MB cell differentiation.

59 ## Introduction

60 The Hedgehog (Hh) pathway is one of the major regulators of cerebellar granule neuron
61 precursor (GNP) proliferation. Sonic hedgehog (Shh) protein secreted from Purkinje neurons
62 drives proliferation of GNPs (*1-3*) through transcriptional regulation of *Cyclin D1* and *N-myc* (*4,*
63 *5*) among other targets. Despite ongoing exposure to Shh, GNPs leave the cell cycle and
64 undergo timed and reliable differentiation, a switch that occurs correctly about 50 billion times
65 in the developing human brain. When differentiation and neurogenesis fail, for example due to
66 Shh pathway mutations that lead to unrestrained Shh target gene activation, GNPs continue to
67 proliferate and may form medulloblastomas (MBs). Yet even in genetic models of MB that are
68 100% penetrant, where Shh target genes are dramatically activated, the vast majority of GNPs
69 still differentiate into functional granule neurons (GNs) (*6*). Thus, regulation that promotes
70 differentiation has the potential to overcome a potent mitogenic signal.

71 GNPs are the cell type of origin for the Shh subtype of MBs, which make up a quarter to a
72 third of MBs. Children with Shh MB are treated intensively with surgical resection followed by
73 craniospinal radiation, one year of multi-drug chemotherapy, and targeted inhibition of the Hh
74 pathway using Smo inhibitors. Unfortunately, in patients with germline Hh pathway mutations,
75 or intratumoral mutations in *P53*, the five-year overall survival is halved, from 81% to 41% (*7,*
76 *8*). Making matters worse, patients with *P53* mutations often have amplifications in
77 downstream targets like *GLI2* and *NMYC* (*9, 10*), meaning that they will not respond to
78 inhibitors that target the SMO protein.

79 An alternative therapeutic approach is to force tumor cells into terminal differentiation,
80 which can be less toxic than alkylating chemotherapy or radiation (*11-13*) and does not rely on
81 apoptosis or other cell death machinery. The optimal procedure for inducing terminal
82 differentiation is likely to vary from cell type to cell type, since differentiation of neurons
83 depends on different genes than, for example, differentiating blood cells. Neuronal
84 differentiation of MB does occur spontaneously, as it has been commonly observed in human
85 MB pathology specimens for over 30 years (*14-16*). BMP4 induces differentiation of MB cells,
86 reflecting its normal effect on GNPs (*17, 18*). Unfortunately, no pharmaceutical BMP agonist
87 currently exists. Developmental regulation of cerebellar granule neurons potentially provides
88 us with blueprints for engineering a differentiation therapy that is specific to Shh-subtype MB
89 differentiation.

90 GNPs undergo approximately eight symmetric divisions (*19*), during transit amplification in
91 the external granule layer (EGL) (Fig 1A). As GNPs divide they travel inward from the pial
92 surface, eventually exiting the cell cycle. GNP movement, morphogenesis, and synapse
93 formation lasts for about 10 days after cell cycle exit (*20-22*). Following the last mitosis the cells
94 remain in the inner EGL (iEGL) for approximately 48 hours. While in the iEGL the GNs begin to
95 extend two lateral processes, then a deep process (Fig 1B). Each GN nucleus migrates inward
96 through the deep process, along Bergmann glia and past the Purkinje cell layer, into the Internal
97 Granule Layer (IGL). The final shape of a GN is a T, with most of the cell's three processes
98 located in the molecular layer and the nucleus in the IGL. For each step of GNP differentiation,
99 positive and negative regulators have been discovered (*23, 24*). The extensive movement and

100 morphological changes involve the changing expression of hundreds of genes, as shown by
101 recent transcriptional profiling (*25*).

102 We set out to explore epigenetic regulation of genes whose expression increases during
103 differentiation. Many genes whose transcription change during differentiation encode
104 chromatin-remodeling complexes, implying coordination at the level of transcription (*25*). In
105 addition, SHH MB harbor somatic mutations in genes which impact a number chromatin
106 modifying complexes including genes that impact H3 methylation at K27 and K4 (*26*). A
107 mechanism that represses pro-differentiation genes potentially could be inhibited by an anti-
108 cancer drug and would potentially stimulate differentiation of MBs.

109 Our plan was to comprehensively describe histone modifications and critical transcription
110 factors at promoters and enhancers of genes that become active during GNP development, to
111 discover inhibitors of differentiation. We found that more than half of the GNP differentiation
112 genes are associated with histones modified to be H3K27me3 and H3K4me3. H3K27
113 methylation is carried out by the Enhancer of zeste homolog 2 (EZH2) histone
114 methyltransferase, a component of one of the Polycomb Repressive Complexes (PRC2) that
115 were discovered in Drosophila (*27, 28*). H3K4me3 is formed by the MLL complex (*29*) and was
116 not further investigated in our studies. The frequency of H3K27 modifications suggested that
117 inhibition or mutation of EZH2 could lead to premature differentiation, and perhaps to
118 differentiation and growth cessation by MB cells. In *Ezh2* mouse mutants we observed
119 accelerated differentiation of GNPs that had exited the cell cycle. We were able to induce

120 differentiation of MB cells by combining an EZH2 inhibitor with a CDK4/6 inhibitor that arrested

121 cells in G0.

122

123 # Results

124 **Identification of genes activated at the onset of GNP differentiation**

125 We used Percoll fractionation to enrich for GNPs from wild-type mouse cerebella at three
126 key stages, proliferation initiation (P1), peak proliferation (P7), and the onset of differentiation
127 (P14), and then extracted RNA (Materials and Methods; the RNA preparations used are
128 diagrammed in blue in Fig. 1C). We purified earlier-stage GNPs from E15.5 mouse embryos;
129 these had seen little or no Shh (Materials and Methods). E15.5-stage GNPs were also isolated
130 by fluorescence-activated cell sorting (FACS) from E15.5 mice harboring a *Math1-GFP* reporter
131 (*30*). *Math1-GFP* is expressed in neural progenitor cells from the dorsal neural tube, adjacent
132 to the roof plate, that are committed to a GNP lineage. The reporter remains active until GNPs
133 complete their final mitosis.

134 Data for GNPs from stages later than P14 were obtained using the Translating Ribosome
135 Affinity Purification (TRAP) dataset made available by the Hatten lab (*25*). TRAP data were
136 obtained by purifying mRNA from post-proliferative stages of GNP differentiation (P18, P28) in
137 cells expressing *NeuroD1,* which is transcribed as GNs exit from the cell cycle. TRAP has the
138 benefit of allowing detection and quantification of RNA in the delicate granule neuron
139 processes which are otherwise lost when cerebellar tissue is broken up. *NeuroD1* is not
140 expressed at E15, so earlier time points were not accessible using TRAP. Our RNAseq data were
141 combined with the NeuroD1-TRAP data (23) to achieve a picture of transcription from the
142 earliest stages of GNP formation at E15 to their terminal state at P56.

143 To identify genes that increase transcription during differentiation we followed a multistep
144 process (Fig. 1C). First, genes were excluded if their transcript level was below a cutoff,
145 established using the maximum expression time point of each dataset in both our RNAseq and
146 the Hatten lab TRAP data, and fitting a mixture of two probability distributions to the bimodal
147 data (expressed and unexpressed). Next, we excluded genes that were potentially
148 contaminants from other cell types. Percoll-fractionated samples from P7 mouse cerebellum
149 typically contain about 95% GNPs and 5% contaminating cells (Fig. 1C, blue v. gray). Genes that
150 are highly expressed in non-GNP cerebellar cells, and scarcely expressed in GNPs, were
151 identified and excluded based upon single-cell RNAseq (scRNAseq) of the developing mouse
152 cerebellum from E10 to P14 (*31*). 1874 genes that were represented by transcripts in bulk
153 cerebellar RNA were determined to be likely contaminants based upon the results of the
154 scRNAseq. Third, genes that vary substantially during the cell cycle were removed as well.

155 GNP differentiation genes were grouped according to when during development they had
156 maximum transcript abundance. Genes whose transcript levels changed less than 2-fold
157 between developmental stages were categorized as unchanged.

158 2050 genes were most highly represented in RNA between P14 and P56 and were
159 categorized as differentiation genes. Some peaked early in differentiation, and some peaked
160 during maximal GNP proliferation from P1 to P7. We used the time at which a gene's transcript
161 reached 50% of its maximum (t50) to describe when genes were undergoing the most
162 transcriptional changes (Fig S1A-C). If a gene reached 50% of its maximum transcript level
163 before P0 it was set aside. Our focus on differentiation therapy means we are primarily

164 interested in genes that increase after the period of peak proliferation, as this is most similar to
165 MB.

166 787 genes increased 4-fold to 12.4 fold at or after P14, comparing the lowest to highest
167 contiguous time points, and were categorized as differentiation genes (Fig 1C and Supplemental
168 Table 1). Many of the differentiation genes are involved in neuronal function with 181 genes
169 impacting membrane potential or synaptic signalling, which includes 45 ion channels and 45
170 transporters. Genes involved in cell morphogenesis make up another 57 genes including cell
171 adhesion proteins and another 28 proteins involved in the cytoskeleton. In addition to these
172 terminal effectors of building a functional neuron we also see an increase in 50 transcription
173 factors, which could have extensive downstream impact on transcription (Supplemental Table
174 2).

175 Transcripts of a different set of 440 genes were highest (>= 4 fold) during proliferative
176 stages P0-P7. As expected, these proliferation genes included *Gli1,* a direct transcriptional
177 target of the Shh signal transduction pathway that drives GNP proliferation, as well as cell cycle
178 regulators including the G1/S phase cyclin *Ccnd1.* The majority of the genes that have *lower*
179 RNA abundance as GNPs approach cell cycle exit are known regulators or components of the
180 cell cycle such as components of the E2f-Rb complex which controls expression of S-phase cell
181 cycle related genes. Transcript levels for a third set of 783 genes were highest (>= 4-fold
182 change) in the E15 pre-Shh GNPs (*32, 33*).

183 We checked a putative differentiation gene to see if its protein abundance reflected the
184 observed changes in RNA levels. P7 cerebellar sections (Fig S1E) and GNPs differentiated *in*

185 *vitro* (Fig S1F,G) had changes in protein abundance that agree with the RNASeq results. *Cbx7*
186 was among the differentiation genes that had increased transcripts at P14 compared to P7.
187 Levels of Cbx7 proteins increase in the inner EGL and further in the IGL (Fig S1E), where GNPs
188 have recently exited the cell cycle and initiated the first stages of differentiation.

189 GNP division, differentiation, and migration can occur during a wide developmental
190 window, from P3 to P10 (*19*). The densely packed nuclei within the EGL and IGL preclude
191 accurate quantification of protein levels. To avoid these problems we used GNP culture, which
192 permits accurate and automated single-cell quantification. The murine *Math1* bHLH
193 transcription factor was used to distinguish dividing from non-dividing cultured GNPs. *Math1*
194 expression stops when the GNPs stop dividing. *Math-1* reporter GFP (*30*) fluorescence allows
195 classification of GNPs as differentiated or proliferating. To estimate the changes in Cbx7
196 during differentiation in culture we compared 6h Atoh1 high cells (dividing GNPs) to 48 h Atoh1
197 low cells (differentiated GNs). Cbx7 was 3.3 times higher in the differentiated GNs then the
198 dividing GNPs (Fig S1 D-G).

199 The transcription of the 787 differentiation genes varies in the exact timing of transcription
200 activation, as reflected in Fig S1A. A regulator of a set of differentiation genes, among the 787,
201 might be a good target for therapeutic manipulation to force MB cells to differentiate. Based
202 upon gene expression patterns, SHH-subgroup MB cells are highly similar to Shh-exposed
203 dividing P7 GNPs (*31*) . Both cell types rely on Hh signaling as a mitogen (*1*). Mutations of Hh
204 components in the GNP lineage are adequate to induce medulloblastomas (*6*). Further
205 experiments examining epigenetic regulators therefore focused on P7 GNPs.

206 **The chromatin repression modification H3K27me3 is present in P7 GNPs on half the 787**
207 **differentiation genes, and correlates with H3K4me3 and poised RNA Pol2**

208 To gain insight into the transcriptional regulation of differentiation genes, we
209 investigated the chromatin state of P7 GNPs. The positions and abundance of six histone
210 modifications and two chromatin-associated proteins were measured using ChIP-Seq:
211 H3K27me3, H3K27ac, H3K36me3, H3K4me3, H3K4me1, H2Aubi119, Ring1b, and Pol2S5. We
212 selected the histone modifications and known chromatin bound proteins for ChIP based on
213 known markers of promoters, enhancers, and to broadly assess transcriptional repression**.**
214 Modifications associated with Polycomb-mediated transcriptional repression were mapped,
215 including H3K27me3, which is produced by the PRC2 complex (*34*), H2Aubi119, which is
216 produced by the PRC1 complex (*35*), and Ring1b, which is a core component of the PRC1
217 complex and is the ubiquitin ligase that catalyzes H2Aubi119 modifications.

218 Another form of transcriptional repression employs CpG island DNA methylation**.** DNA
219 methylation was measured using methylated-CpG island recovery assay (MIRA), which uses
220 recombinant MBD protein to bind double-stranded methylated DNA (*36*).

221 Protein modifications at active promoter regions were assessed, including H3K4me3, S5-
222 phosphorylated RNA polymerase 2 (Pol2S5), (which labels paused RNA polymerase), H3K4me1
223 (which is associated with active enhancer regions), and H3K27ac (which is found at active
224 promoters and enhancers) (*37-40*). DNA accessibility was assessed by ATAC-Seq, which is based
225 upon the bias for Tn5 transposition towards open chromatin (*41*). To quantify the amount of a
226 histone modification at a given gene we quantified the number of reads within 250 BP of the
227 transcriptional start site (TSS). Several of the histone modifications, including the

228 transcriptionally repressive modifications accumulate at the TSS and extend towards the gene
229 body and upstream (Fig S2C,D). This extension of the histone modifications has been shown to
230 be biologically relevant for H3K27ac at super-enhancers (*42*) and for H3K27me3 at permanently
231 repressed genes like Hox genes. To better separate strongly marked genes from moderately
232 marked genes we extended the quantified region to include significantly bound DNA regions
233 farther from the TSS (Materials & Methods).

234 Of all the histone modifications and histone-associated proteins assessed for selective
235 presence with the differentiation genes, the frequent presence of H3K27me3 was most striking.
236 Of the 787 differentiation genes 447 (57%) had H3K27me3 within 250 BP of the TSS (Fig 2B). To
237 identify important modifications we calculated enrichment, meaning the amount of a
238 modification in the 787 differentiation genes compared to the amount in either all genes or in
239 expressed genes during the GNP time-course. H3K27me3 was 2.3 times more frequent near
240 differentiation genes compared to all expressed genes at P7 (p-val $7.54 \times 10^{-147}$, hypergeometric
241 BH adjusted) and 2.7 times more frequent compared to all genes (p-val $7.14 \times 10^{-198}$,
242 hypergeometric BH adjusted) (Fig. 2A). H2Aubi119, a repressive modification made by Ring1b,
243 a component of the PRC1 complex, was also more frequent at the differentiation gene set with
244 2.17 enrichment over all genes (p-val $1.15 \times 10^{-245}$, hypergeometric BH adjusted) and 1.89 over
245 all expressed genes at P7 (p-val $3.71 \times 10^{-156}$, hypergeometric BH adjusted).

246 The frequent presence of H3K27me3 modifications suggests that PRC2 may repress
247 differentiation genes during GNP transit amplification. The PRC2 complex contains the
248 methyltransferase EZH2, which carries out H3K27 methylation. From past studies (*43*) we
249 know that PRC2 is present at specific chromatin regions, where it functions as a transcriptional

250 repressor. The amount of H3K27me3 present regulates whether repression is temporary
251 (moderate levels) or permanent (high levels) (*44-46*). The differentiation genes have a
252 moderate amount of H3K27me3 (Fig S2A-C). Only three differentiation genes had high levels of
253 H3K27me3. The other, non-differentiation, genes within the high H3K27me3 group included
254 Hox cluster and transcription factors associated with alternative fates or earlier lineages. As an
255 example, *Cbx7*, a differentiation gene, has moderate K27me3 while Lhx9 and Hoxa10 have high
256 K27me3 (Fig SC). Very highly H3K27me3-modified genes are thought to be permanently
257 repressed (*47*).

258 In addition to the amount of H3K27me3, whether PRC2 repression is transient or long-
259 lived depends on its association with other histone marks or protein complexes. For example,
260 H3K27 methylation may occur in association with active-gene modifications such as H3K4me4
261 and/or poised RNA polymerase II (*48*). This kind of arrangement is known as a bivalent
262 promoter, transcriptionally repressed but poised for increased transcription (*49, 50*). In
263 contrast, PRC2 can establish more permanent repression when associated with certain PRC1
264 variants (*51*). However, these are heterogeneous complexes, and changing select PRC1 subunits
265 allows the association with bivalent promoters as well (*52*). H3K27me3 can recruit the
266 machinery for DNA methylation (*53*), driving permanent repression.

267 To distinguish possible roles of PRC2 in GNPs we examined the relationship between
268 H3K27me3 and H2Aubi119 (a marker of PRC1 complex) or H3K4me4 (a marker of active
269 promoters) at differentiation genes that have H3K27me3. H3K27me3-marked differentiation
270 genes have both H3K4me3 and PRC1 complex (H2Aubi119). DNA methylation was detected in

271 only 4 percent of differentiation genes, indicating that this form of repression is mostly not
272 active there.

273 The association of H3K27me3 with other modifications at differentiation genes is
274 represented as a chart (Fig 2B). Each modification is represented by a column that shows the
275 numbers of modified and unmodified genes. The columns are organized from left to right
276 according to the number of genes that are also marked by H3K27me3. The red band shows
277 genes containing H3K27me3 which share other modifications. Of the 447 H3K27me3-marked
278 differentiation genes, 87 % also had H3K4me3 and 84.3% had paused RNA polymerase. PRC1
279 occupancy on the H3K27me3-bound differentiation genes was frequent: 89 % of the 447 genes
280 had significant H2Aubi119. The frequent associations between H3K27me3 and H2Aubi119 or
281 H3K4me3 are also seen with a scatter plot (Fig S2 D,E), where 373 (83%) of the differentiation
282 genes bear all three modifications.

283 Thus at P7 many of the 447 differentiation genes had nearby PRC2 complexes, PRC1
284 complexes, and markers of active promotors such as H3K4me3 and RNA Pol2Ser5P (paused
285 RNA polymerase 2). These results suggest that about half of the differentiation genes have
286 bivalent or poised promoters containing both PRC2 and PRC1. Removal of these modifications
287 in the normal course of development, or engineered removal in MB cells, may cause de-
288 repression of these genes and early differentiation.

289 **Ezh2-mediated H3K27 methylation delays differentiation of GNPs**

290 The H3K27me3 histone modification, associated with gene repression, is enzymatically
291 carried out by the protein complex PRC2. The presence of H3K27me3 modifications at 447 GN

292 differentiation genes at the P7 stage suggests that PRC2 may be blocking differentiation. In
293 that case differentiation of GNs, or perhaps MBs, would require relief from PRC2 repression.
294 We tested this hypothesis using mice carrying a mutation in *Ezh2*, which is the enzymatic
295 component of PRC2 that catalyzes formation of H3K27me3. Homozygous *Ezh2* knockout mice
296 die as embryos (*54*), so studying postnatal cerebellar development required conditional
297 knockout mice. Mice with LoxP sites flanking the DNA encoding the SET domain of *Ezh2* (*55*)
298 were crossed with *Math1-Cre* mice (*56*). The SET domain is required for Ezh2 to function as a
299 methyltransferase (*57*) and maternal depletion of the SET domain in mice causes significant
300 growth retardation (*58*).

301 As a consequence of crossing the *Ezh2* Lox-P mice with the *Math1-Cre* mice, H3K27me3 is
302 reduced in the granule neurons (Fig S3 A-C). *Ezh1*, a paralog of *Ezh2* that is present throughout
303 GN development is a weaker methyltransferase than *Ezh2* (*59*). Even with *Ezh1* functioning,
304 conditional loss of *Ezh2* led to dramatic loss of H3K27me3 from GNPs and GNs, as shown in P7
305 cerebellar slices (Fig S3 A panel II vs VI, yellow arrow) and cultured GNPs (Fig S3 C panel II vs IV,
306 yellow arrow).

307 The most notable phenotype of the *Ezh2* cKO mice is a blurring of the boundary between
308 the inner external granular layer (iEGL) and the molecular layer (ML; Fig 3B-C, magenta and
309 cyan arrow). GNs within the inner EGL (iEGL) permanently exit the cell cycle and remain there
310 as they extend parallel fibers. GNs within the iEGL express the cell cycle inhibitor p27. In the
311 *Ezh2* cKO the iEGL is more diffuse and blends into the ML (Fig 3A compare cyan arrows). To
312 facilitate quantification of the EGL blurring we collapsed 2D fluorescent images into line

313 segments (Fig 3D). P7 cerebellar slices were stained with anti-p27 to label post-mitotic EGL
314 cells, NeuN antibody to identify the IGL, and DAPI to mark all nuclei. For each channel,
315 measurements were made along a line from the pial border on the outside to the IGL. The 581
316 lines (266 WT and 315 *Ezh2* cKO ) were aligned and averaged, in sets according to genotype (Fig
317 3E). The normalized p27 intensities show a spreading of iEGL, blurring the boundaries with the
318 IGL and ML. The ML blurring, was quantified as an increase in the p27 at the junction of the
319 iEGL and ML in the *Ezh2* cKO (Fig 3D; compare the cyan arrows). To quantify across replicates,
320 we compared *Ezh2* cKO and WT at a point within the ML where the *Ezh2* cKO had the highest
321 relative p27 fluorescence (Fig 3E).

322 The sizes of the layers of the cerebellum are largely unaffected by *Ezh2* cKO (Fig 3G,H). **T**he
323 different layers of the cerebellum were measured in slices stained with anti-p27, NeuN
324 antibody, and DAPI (Fig. 3F). No significant differences were observed in the thicknesses of the
325 oEGL, iEGL, ML, or IGL (Fig 3G,H). Due to the diffuse EGL/IGL-ML boundary in the cKO, p27
326 fluorescence intensities within the iEGL (where GNPs begin differentiation) and IGL (where
327 post-mitotic GNs reside) were reduced 25% and 23% (Fig 3I). These findings are consistent with
328 the loss of *Ezh2* function not altering the overall structure of the cerebellum, but instead
329 specifically affecting GN differentiation.

330 *Ezh2 cKO*$^{-}$ GNPs labeled with a 48 h EDU pulse migrated from the EGL prematurely (Fig.
331 S3 D-F). To distinguish early migration out of the oEGL from stalled GN migration within the
332 ML, GNPs going through S-phase were labeled with EDU and harvested 48 hours later. In WT
333 mice there is dense EDU labeling of the iEGL, and GNs lining up along the border with the ML

334 (Fig S3 D, panel III versus VIII, yellow arrows). In the *Ezh2* cKO, EDU-labeled cells are within the
335 diffuse iEGL and within the ML (p-val 0.024), mirroring what was seen with p27
336 immunofluorescence (Fig S3E,F). We conclude that, in *Ezh2* mutant mice, GNs prematurely exit
337 from the EGL into the ML, a movement typical of wild-type GNs that have stopped dividing.
338 The hypothesis that PRC2 blocks cell differentiation is consistent with the *Ezh2* mutant results,
339 because early de-repression of differentiation genes would cause premature EGL cell migration.

340 GNPs cultured from *Ezh2* cKO mice, compared to normal, had more differentiated cells but
341 the same fraction of dividing cells. That fits with the idea that loss of *Ezh2* allows premature
342 activation of differentiation genes. To further test the impact of *Ezh2* cKO on differentiation,
343 we cultured GNPs with Shh and monitored *Map2* (Fig. 4A,C), a marker for process extension,
344 and *NeuN*, a marker of differentiated GNs. Process extension was measured using Neuroncyto
345 2 (*60*), which reveals cell processes and assigns them to a cell body (Fig. 4B,D). *Ezh2* cKO GNPs
346 had a 37.6% increase (p-val 0.007) in average process length compared to control (Fig 4E).
347 Next, we separated the cells into groups based upon process length (Fig 4F). WT cells had a
348 19.2 % higher proportion of cells with no process (49.2 % WT vs. 30% in *Ezh2* cKO; p-val 0.019)
349 or a process less than 5 pixels long (p-val 0.0047). *Ezh2* cKO cells had processes 10 pixels and
350 longer 20.1% more often (39.3 WT versus 59.4 *Ezh2* cKO). Thus loss of *Ezh2* led to more of the
351 longer processes, an indicator of differentiation, in cultured GNPs.

352 Cell cycle stage and differentiation were quantified using staining for DAPI (to show all
353 nuclei), Ki67 (to show dividing cells), and NeuN (to show post-mitotic neurons) (Fig S4A). The
354 fraction of total cells that were NeuN-positive in *Ezh2* cKO cultures was 13.9 % compared to 9.8

355 % in WT (p-val 0.008) (Fig S4C). The amount of NeuN fluorescence increases on the per-cell
356 histogram (Fig S4B). No significant change in the number of cells that were in G1 (p-val 0.107)
357 or G2 (p-val 0.087) occurred, with cells more often being in G1 in *Ezh2* cKO and in G2 in WT (Fig.
358 S4C). *Ezh2* appears to be a cell-intrinsic regulator of differentiation timing; its loss hastens
359 process extension and nuclear migration out of the EGL.

360 **During normal development, *Ezh2* transcript and protein levels decrease as GNPs**
361 **differentiate**

362 Reduced PRC2 activity as GN differentiation commences could be due either to reduced
363 Ezh2 protein levels or to functional inactivation. Among genes encoding components of
364 repressive chromatin complexes, transcript levels for *Ezh2* and *Cbx7* changed the most during
365 early GN development, with *Ezh2* transcript being reduced 8.8 fold after P7 (Fig 5A,B). GNP cell
366 cycle exit coincides with a reduction in Ezh2 protein level, as shown by reduced staining
367 intensity in the iEGL (Fig 5C). To further explore this observation, P7 GNPs freshly isolated from
368 *Math1>GFP* reporter mice were plated to observe differentiation. As early as 6 hours after
369 plating, the average level of Ezh2 was lower in GNs that had begun to differentiate, as
370 determined by low Math1-GFP levels. Relative fluorescence for Ezh2 continued to drop at 24
371 hours of culture (Fig 5D). Thus cell cycle exit strongly correlates with decreased Ezh2 levels in
372 cultured cells and in vivo.

373 The results so far suggest that Ezh2-based H3K27me3 modifications at promoter regions
374 delay transcription of many differentiation genes during GNP proliferation. Once GNPs
375 complete their final mitotic division and enter G0 in preparation for differentiation, reduced

376 *Ezh2* function may foster activation of the GN differentiation program. Can this knowledge be
377 applied to manipulate MB cells?

378 **Medulloblastoma cells also H3K27-trimethylate GN differentiation genes**

379 In MB cells, as in dividing GNPs, repressive chromatin regulators may prevent expression of
380 GN differentiation genes to maintain a pro-proliferative state. Indeed, 95% of the 447
381 differentiation genes that are H3K27-marked in GNPs are repressed in MB cells compared to
382 GNs (Fig 6C). To determine whether GN differentiation genes are stably repressed in MB, we
383 measured chromatin markers and mRNA transcript abundance in MB samples from *Ptch1*$^{+/-}$
384 mice. *Ptch1* encodes the Hedgehog receptor, a negative regulator in the pathway, so in these
385 mice, and in humans with the same kind of mutation, derepressed Hedgehog target genes
386 increase the frequency of MB. RNAseq was used to compare transcript populations in MBs
387 from *Ptch1*$^{+/-}$ mice to P1, P7, and P14 GNPs. As expected, MB transcripts correlated most with
388 transcripts from rapidly dividing P7 GNPs ($R^2$ = 0.79) compared to P1 ($R^2$ = 073 , Fig S6 B) or P14
389 ($R^2$ = 0.52, Fig S6 C).

390 In MB cells, three-quarters of the GN differentiation genes have H3K27me3 at their
391 promoters (Fig S6 A,C). The Pearson correlation between MB cells and P7 GNPs was also
392 strong for histone markers, with H3K27me3 being 0.79, H2Aubi119 being 0.87 and H3K4me3
393 being 0.95 (Fig. S6A). Among genes that increase expression during GN differentiation, only
394 27% of the H3K27-methylated GN differentiation genes did not have H3K27me3 in MB cells (Fig
395 6 A,C). The majority of GN differentiation genes are persistently repressed in MB.

396 **In human SHH-subtype medulloblastomas, higher levels of *EZH2* transcript correlate with**
397 **lower-level expression of GN differentiation genes**

398 The inverse relationship between GN differentiation gene transcription and Ezh2 levels
399 holds true in human MB tumors as it does in mouse MBs and developing mouse cerebellum.
400 The levels of *EZH2* transcription from 223 primary human samples of *SHH*-subtype MB (*9*) were
401 compared to the levels of GNP differentiation gene transcripts. Samples were ranked in terms
402 of *EZH2* mRNA level (Fig 7A). The 30% of the tumors with the least *EZH2* RNA were compared to
403 the top 30% (Fig S7A). GN differentiation gene transcript levels were on average 1.3 fold
404 higher in tumors with low EZH2 transcript than in tumors with high EZH2 (Fig S7A).

405 Comparing human genes that were differentially expressed in *EZH2*-high vs *EZH2*-low
406 SHH MB samples with the expression of their mouse homologs revealed a striking pattern (Fig
407 7B). Genes that were significantly more highly transcribed in human MBs that had relatively
408 low *EZH2* RNA were 26-fold enriched for genes whose transcription increases during mouse
409 GNP differentiation (Fig 7C). 60% of the human genes that had low expression when *EZH2* RNA
410 was high were among the mouse GNP differentiation genes (343/570). The amount of Ezh2
411 transcript in each individual tumour was also anticorrelated with the transcript levels of the
412 individual differentiation genes (Fig S7B,C). The average Pearson correlation for the
413 differentiation genes was -0.24 indicating a negative correlation (Fig S7B,C). Thus the
414 relationship between *EZH2* transcription and differentiation gene transcription is maintained in
415 human MBs.

416 Patients with high *EZH2* RNA tumors had significantly worse 5-year (*EZH2*-high 73% versus
417 *EZH2*-low 91%) and 10-year (*EZH2*-high 64% versus *EZH2*-low 84%) survival (Fig 7D), so patients
418 with lower *EZH2* RNA and more differentiation gene expression have a better prognosis.

419 **Combined Ezh2 inhibitors and CDK4/6 inhibitors force MB cells to undergo neuronal**
420 **differentiation**

421 Mouse MB cells isolated from *Ptch1*$^{+/-}$ mice (*61*) were plated on laminin-coated plates and
422 cultured for 72 hours in serum-free medium, with or without small molecule inhibitors (Fig 8A).
423 We measured rates of proliferation and differentiation using 2 combinations of antibodies and
424 dyes. In one type of experiment, we used anti-pRb (Ser807/811) to label G1/2 versus G0 and
425 NeuN to label differentiated cells (Fig 8A,B). In a second type of experiment, the antibody
426 combination was p27, which identified quiescent G0-arrested MB cells, and Atoh1, which is
427 only present during MB proliferation (Fig S8A,B). Cycling MB cells have high Atoh1 and low p27
428 if in G1/S/G2 (green in Fig. S8A) or high p27 if in G0 (yellow in Figure S8A). Cells embarking on
429 differentiation (red in Fig. S8A) have high p27 but relatively low levels of Atoh1. NeuN marks a
430 later stage of development than p27 presence or loss of Atoh1.

431 Untreated MB cultures had 70.2/43.6% (pRb high / Atoh1 high p27 low) dividing cells and
432 2.0/14.2% (NeuN high / Atoh1 low p27 high) differentiating cells. Cultures treated with Ezh2
433 inhibitor (5 uM UNC1999) had 50.4/18.6% (pRB high /Atoh high p27 high) dividing cells and 4.6/
434 35.2% ( NeuN high / Atoh1 low p27 high) differentiating cells (Fig 8B, Fig S8B). Ezh2 inhibition
435 caused a 21 % increase in the fraction of differentiated cells, based upon measuring Atoh1 and
436 p27 (p-val < 0.001) and a 2.6 % increase in NeuN positive cells (p-val < 0.001). For UNC1999,
437 previous studies of cultured cells showed that a dose of 1 to 5 uM caused substantial reduction

438 in H3K27me3 activity without substantial toxicity (*62*). Thus induction of differentiation genes
439 using Ezh2 inhibitor reduced but did not stop MB cell growth, in keeping with a lack of effect on
440 MB frequency due to genetic removal of Ezh2 function. *Ptch1*$^{+/-}$ mice were crossed with *Ezh2*$^{fl/fl}$
441 Math1-Cre mice. About 15% of the *Ptch1*$^{+/-}$ mice develop MBs. *Ezh2* cKO did not affect the rate
442 of MB formation in *Ptch1*$^{+/-}$ mice. MB formation occurred in 14.86% (n = 74) who were Cre$^{+/-}$
443 and 14.28 % (n = 84) in Cre$^{-/-}$ animals.

444 Normal development may be informative about how to stop MB cells from growing. During
445 normal differentiation, GNPs would first enter G0 arrest, then GNP differentiation genes would
446 be de-repressed as Ezh2 is reduced. To stop MB cell proliferation, the same two steps might be
447 required: going into G0 arrest and then differentiating. MB cultures treated with CDK4/6
448 inhibitor (1 uM Palbociclib) to drive them into G0 (*63*), had 18.1/15.4% (pRb high / Atoh high
449 p27 low) dividing cells and 15.9/26.0 % differentiating cells (NeuN high / Atoh1 low p27 high).
450 Thus an inhibitor that pushes MB cells toward G0 is does increase rates differentiation more
451 than the Ezh2 inhibitors alone but still at relatively low rates (Fig 8B, Fig S8B).

452 Dual treatment with Ezh2 inhibitor and CDK4/6 inhibitor produced the highest percentage
453 of terminally differentiating MB cells 22.8/43.0 % (NeuN high / Atoh1 low p27 high) with only
454 9/6.8 % (pRb high / Atoh1 high p27 low) percent of cells dividing (Fig 8B, Fig S8B). The
455 combination of Ezh2 inhibitors and CDK4/6 inhibitors increased the rate of differentiation by
456 7% for NeuN positive cells (p-val 0.004) and 17% for low of Atoh1 with high p27 (p-val < 0.001).
457 MB cells treated with both 5uM UNC1999 and 1um Palbociclib developed thin neuron-like
458 processes, that contain the F-actin stain phalloidin (Fig S8B xiii). In contrast, after treatment

459 with CDK4/6 inhibitor alone, no such processes were observed and the cells appeared similar to
460 dividing MB cells (Fig S8B x). It should be noted that differentiated GN require changes to the
461 media for long term survival which could limit the time an MB cell could survive late into
462 neuronal differentiation.

463 Combining a CDK4/6 inhibitor with an Ezh2 inhibitor could be toxic to dividing cells. The
464 increase in percentage of differentiated cells would then reflect more robust survival of
465 differentiated cells vs proliferating cells. If selective survival explained the results, then the
466 absolute number of differentiated cells should be similar in untreated and doubly treated cells.
467 Instead, combining 5uM UNC1999 and 1 uM Palbociclib produced 2.2 to 4.68 times more
468 differentiated cells compared to control cells not treated with any drug (Fig S8C). This suggests
469 that combining Ezh2 and CDK4/6 inhibitors drove conversion of dividing cells into differentiated
470 cells, rather than causing selective death of dividing cells.

471 A key advantage of differentiation therapy over anti-proliferative approaches is that
472 terminally differentiated neurons should not re-enter the cell cycle even after the treatment is
473 terminated. MB cells in culture were treated with 1 uM of the CDK4/6 inhibitor alone or in the
474 presence of various doses of Ezh2 inhibitor. After 72 hrs, all drugs were washed out and the
475 cells cultured for an additional 24 h (Fig. 8C). As previously, cells were labeled using anti-pRb
476 (Ser807/811) and NeuN (Fig. 8D). When CDK4/6 inhibitor was used alone, following drug wash
477 out 40.8 % of MB cells re-entered the cell cycle (Fig 8E). Thus, with only CDK4/6 inhibition, MB
478 cells can rapidly re-enter the cell cycle. Only 14.2 % of cells treated with both inhibitors re-
479 entered G1/2. Again, we saw an increase fraction of differentiated from 14.5 % of cells to

480 21.9% (p-val 0.006) (Fig 8E) and in the total number of differentiated cells by 1.68 times (p-val

481 0.016) comparing dual Ezh2 and CDK4/6 inhibitors compared to CDK4/6 inhibitors alone (Fig

482 S8D). The combination of Ezh2 inhibitors with CDK4/6 mediated cell cycle arrest achieves the

483 most important therapeutic goal, to irreversibly prevent cell cycle re-entry.

484 ## Discussion

485 The parallels between early cerebellar development and MB formation provide an
486 opportunity to study key regulators of normal development in the context of tumor cells, with
487 the goal of stopping tumor growth. During normal cerebellar development, GNPs proliferate
488 under the mitogenic effect of the Sonic hedgehog pathway. Following a period of transit
489 amplification, GNPs exit the cell cycle and terminally differentiate into granule neurons, the
490 most abundant neuron in the brain (Fig 1). In MBs, the SHH pathway is aberrantly activated
491 through mutations that inactivate inhibitory elements of the pathway (eg Patched or Sufu) or
492 through amplification of activating elements (eg *Gli2* amplification). As a result, cells fail to exit
493 the cell cycle and can ultimately give rise to a tumor. A large body of evidence describes the
494 morphological (*64*), transcriptional (*65*), and post-translational modifications (*66*) similarities
495 between transit-amplifying GNPs and medulloblastomas.

496 **Ezh2-mediated H3K27me3 broadly represses differentiation genes in GNPS and MBs**

497 Here we undertook a genome-wide identification of the epigenetic regulators and
498 transcriptional changes that occur during the initiation of proliferation, peak proliferation, and
499 early stages of differentiation in GNPs. In agreement with other groups, we find that many
500 genes whose transcription increases as GNPs differentiate have bivalent promoters, with
501 H3K27me3 and H3K4me3 modifications (*67, 68*). Our study also shows PRC1 occupancy at the
502 majority of the H3K27me3-marked differentiation genes (Fig 2). Most PRC1 complex variants
503 and the PRC2 complexes are involved in transcriptional repression, which allows a transient
504 repression of genes required during differentiation. The roles of PRC2 and PRC1 complexes

505 during differentiation has been well described in many different cell types including other types
506 of neurons (*69*), myocytes (*70-72*), cardiomyocytes (*73*) and T-cells (*74*).

507 **Bivalent H3K27me3 and H3K4me3 modifications delay transcription of specific gene sets**
508 **during GNP cell cycle exit**

509 For a cell with complex cytoarchitecture like a neuron, it is important to turn on the correct
510 genes during differentiation and to have those genes turn on at the correct time. Ezh2 is
511 transcriptionally activated by the pRb/E2f1 complex during S-phase expression(*75, 76*). In GNPs
512 the bivalent H3K27me3 and H3K4me3 modifications mark a subset of genes that appear to be
513 sensitive to the drop in Ezh2 function. The subsequent transcriptional activation of genes
514 associated with neuronal differentiation, like ion channels, can in this way be reliably linked to
515 cell cycle exit. The reduction of Ezh2 protein (Fig 5) that occurs as GNPs complete their cell
516 division stage is likely to promote terminal cell cycle exit by allowing de-repression of
517 differentiation genes.

518 What determines the exact timing of transcriptional activation for a given differentiation
519 gene is likely multifactorial. Kdm6b, an enzyme that removes H3K27me3 methylations,
520 significantly influences timing during GNP differentiation (*77*). The abundance of Kdm6b across
521 the H3K27me3 marked differentiation genes may be non-uniform, activating some genes
522 earlier than others. The PRC1 complex has numerous variants, which could fine tune the
523 required delays in GNP differentiation gene expression timing. Another path of H3K27me3
524 elimination can be replicative dilution, where H3K27me3 modifications are depleted by ongoing
525 cell division following Ezh2 activity reduction (*45, 46*). In GNPs, the drop in *Ezh2* expression

526 happens as cells exit the cell cycle, so replicative dilution does not seem to be an important
527 factor.

528 **Ezh2 loss accelerates differentiation but only after cell cycle exit**

529 *Ezh2* cKO allowed early differentiation of GNPs but did not have an impact on transit-
530 amplifying GNPs. During GNP cell division, Ezh2 is highly expressed. As Ezh2 levels drop
531 following cell cycle exit, GNPs activate H3K27me3 modified genes. Premature removal of Ezh2
532 should cause early and/or prolonged activation of differentiation genes. Our *Ezh2* knockout did
533 result in early differentiation but only after the period of transit amplification was complete (Fig
534 3). In cultured GNPs, *Ezh2* cKO did not reduce the number of G1/2 cells. If anything, there was
535 an increase in the number of G1 cells (Fig 4). The phenotype of the *Ezh2* cKO is quite subtle; a
536 previous study did not report a phenotype in the cerebellum in *Ezh2* cKO (*78*). We too found it
537 difficult to observe and quantify the changes to the iEGL. We were alerted to the phenotype by
538 automated analysis of GNP cultures from *Ezh2* cKO mice that revealed increased process
539 extension pointing our attention to the iEGL.

540 **H3K27me3-marked differentiation genes have known GN differentiation phenotypes**

541 Many H3K27me3-marked differentiation genes have known neuronal differentiation
542 phenotypes in cerebellar GNs. One important example is the voltage-gated $Ca^{2+}$ channel genes,
543 which have been linked to GN migration. Of the six channel genes that increase transcription
544 during differentiation, five are modified by H3K27me3. Loss of function of these genes impairs
545 normal GN differentiation. Knockout of *Cacna1a* which codes for Cav2.1 showed clear
546 migration defect in the EGL, with persistence of the EGL at P21 (*79*). Another potent regulator

547 of $Ca^{2+}$ that is critical to GN migration is the NMDA receptor (*80*), which is a ligand-gated
548 glutamate channel. The genes for all four NMDA subunits that transcriptionally increase
549 (NR2BA-D), are modified by H3K27me3. Functional NMDA receptors form when the radially
550 migrating GNs start migrating into the ML (*81, 82*). NMDA receptors undergo subunit switching
551 between migrating and post migratory receptors (*83, 84*). Genetically altering subunit
552 composition leads to an increased rate in migration (*85*) and persistent EGL (*86*), while blocking
553 NMDA receptors reduces migration(*87*). The targets of Ezh2 have developmental phenotypes,
554 and the timing of their production matters.

555 Bdnf and multiple CAMK components that transduce its signal are also H3K27me3-modified.
556 BDNF signaling is a well-established regulator of GN radial migration. The knockout of *Bdnf* (*88,*
557 *89*) or of its downstream pathway components *CaMKKII* or *CaMKIV* (*90*) all cause GN migration
558 defects. The opposite phenotype occurs in response to over-activation of the Bdnf pathway,
559 decreasing the time to differentiation. Transfection of GNPs with a constitutively active CREB,
560 the terminal transcriptional activator of BDNF signaling, accelerated terminal differentiation of
561 GNPs in culture (*91*).

562 From a differentiation therapy perspective, not all differentiation genes are equal. The
563 greatest interest lies with genes that could be activated to prevent subsequent re-entry into the
564 cell cycle. Attempted cell division in differentiated neurons typically leads to cell death as seen
565 with neurodegenerative disease (*92-95*) or to binucleated cells as seen with gangliogliomas (*96,*
566 *97*). Our present results suggest several candidate differentiation genes, but another approach
567 is to manipulate Ezh2 directly and thereby control many of these genes simultaneously.

568 **Ezh2 inhibitors as a potential differentiation therapy**

569 EZH2 inhibitors have been tested in SHH-subtype MB cells and have caused decreased cell
570 viability (*98, 99*) and increased rates of differentiation (*100*). One rationale for using Ezh2
571 inhibitors in MB was that forced expression of *NeuroD1* in MB cells is capable of driving
572 differentiation (*100*). ChIP qPCR analysis had demonstrated that *NeuroD1* is marked by
573 H3K27me3, and Ezh2 inhibitors showed increased rates of differentiation both in culture and in
574 vivo models**.** Therefore, EZH2 inhibition might derepress *NeuroD1* and spur differentiation of
575 MB cells.

576 Our data provide genome-wide context for the previous work by identifying the large
577 number of H3K27me3-modified genes during development and in MB cells. EZH2 drives
578 H3K27me3-mediated repression in *NeuroD1* and in more than half of the 787 genes whose
579 transcription increases in early GN differentiation. The mechanism by which EZH2 inhibition
580 promotes cell death and differentiation of MB cells is likely to depend on its regulation of many
581 genes in addition to repressing *NeuroD1*.

582 **Combined Ezh2 inhibition and cell cycle arrest as a differentiation therapy**

583 A prevailing hope is that properly stimulated differentiation can override tumor cell
584 proliferation, for MB and other cancer types (*101-103*). Differentiation therapy in acute
585 promyelocytic leukemia using retinoic acid (RA), has dramatically extended survival of PML
586 patients (*104, 105*). RA induces the cancer cells to differentiate from a granulocyte precursor
587 into a mature myelocyte that can no longer divide (*106, 107*). Given its transformative effect in
588 AML, RA was trialed for patients diagnosed with MB in hopes of similarly driving differentiation
589 and long-term regression. Unfortunately, RA did not prove effective in MB and phase 2 trials

590 were ultimately halted. RA does cause growth arrest of MB tumous (*108, 109*), but through
591 apoptosis rather than induced differentiation (*110, 111*).
592 Our work suggests a nuanced relationship between proliferation and differentiation in GNPs
593 and MB cells. Ezh2 appears to have a significant role in delaying activation of differentiation
594 genes but *Ezh2* loss or inhibition is not capable overriding the cell cycle. *Ezh2* cKO did not
595 reduce GNP proliferation (Fig 3) and there was only a marginal increase in differentiation with
596 Ezh2 inhibition alone (Fig 8). Neuronal differentiation is a complex process and understanding
597 where and how a given regulator fits into that process is critical to maximizing its use as a
598 clinical differentiation therapy.

599 Additional observations raise concerns about using EZH2 inhibitors as a solo differentiation
600 therapy. First, *Ezh2* cKO did not prevent MB formation in mouse models of MB. SmoM2 mice,
601 who develop MB from unrestrained Hh signalling were crossed with Math1-Cre / Ezh2fl/fl
602 developed MB at 100% penetrance as in normal SmoM2 control mice. The MBs from the *Ezh2*
603 cKO mice were more aggressive than control SmoM2 with intact *Ezh2*, leading to early death of
604 the mice (*78*). *Ezh2* cKO, in Ptch1$^{+/-}$ mice also showed no impact on the rate of MB formation.
605 The reduction in H3K27me3 with *Ezh2* cKO is substantial, exceeding what is possible with an
606 Ezh2 inhibitor, so using Ezh2 inhibitors alone is unlikely to yield differentiation rates high
607 enough to reduce cancer progression. Another concern is that *Ezh2* cKO has no apparent effect
608 on proliferating GNPs. If anything, there were increased numbers of GNPs in G1 in *Ezh2* cKO
609 mice compared to WT mice, indicating that GNPs will not cease dividing when H3K27me3 is
610 strongly depleted. Because MB cells are dividing too, Ezh2 inhibition alone will probably not
611 drive a high rate of differentiation.

612 With regards to forced G0 arrest in MB cells, our observations parallel long term animal
613 experiments, where CDK4/6 inhibitors were used with xenografts of human MB cells. The
614 tumors dramatically regressed when mice were treated with inhibitor (*112*), but three-quarters
615 of the tumors recurred within 60 days of drug removal. This suggests that forced exit of the cell
616 cycle is not sufficient to drive terminal differentiation of MB cells. In our experiments, wash-
617 out of Ezh2 and CDK4/6 inhibitors resulted in cell-cycle re-entry of MB cells within 24 hours (Fig
618 8). When developmental regulation was closely recapitulated using dual inhibitors, driving both
619 exit from the cell cycle and inhibition of Ezh2, we observed significantly higher levels of
620 terminal differentiation without re-entry into the cell cycle following drug wash out.

621 **Barriers to clinical differentiation therapy**

622 Our results suggest two critically important ideas for designing a differentiation therapy for
623 MB. First, our evidence supports the use of Ezh2 inhibition as a strategy for the differentiation
624 of Shh-subgroup medulloblastoma (*100*). The second is that premature transcriptional de-
625 repression by Ezh2 inhibition is not sufficient to cause differentiation in a dividing MB cell. Prior
626 to larger scale testing in animals, more extensive work needs to be done to optimize the
627 duration of cell cycle arrest. A phase I trial of Palbociclib for pediatric brain tumours was
628 recently completed which showed bone marrow suppression at higher doses (*113*). One
629 advantage of differentiation therapy is that the cells may not need to be G0 arrested for more
630 than 72 hours to get induction of differentiation, which means the CDK4/6 inhibitor could be
631 delivered in short pulses. As bone marrow suppression took weeks to months to develop these
632 short pulses will prevent accumulated toxicity (*114*). Continuous administration of an Ezh2
633 inhibitor would be supplemented with 72 hour cyclic period of CDK4/6 inhibition.



634

635 # Materials and Methods

636 **Crosslinking Chromatin immunoprecipiation (ChIP)**

637 The ChIP protocol was adapted from an existing protocol (*115*). Briefly, a single cell
638 suspension of GNPs or MB cells were crosslinked with 1% formaldehyde for 10 min, then
639 quenched with 2.5 M Glycine. Chromatin was sheared using a Bioruptor (Diagenode, Denville,
640 New Jersey) for 6 cycles of 15 minutes (30 sec on, 30 seconds off at maximum power).
641 Following sonication the insoluble material was pelleted. Antibodies were added to the
642 sheared chromatin as indicated by table 1 to 750 ul of chromatin and incubated at 4 C
643 overnight. For each ChIP-seq experiment 3 technical replicates of the immunoprecipitation
644 were performed and pooled after DNA isolation. Protein G agarose beads (Roche) were used to
645 precipitate the antibody bound protein and 4 sequential washes were done with the buffers
646 described in the original paper (*115*). Protein was eluted of beads with 10 mM EDTA and 1%
647 SDS and the DNA was liberated from protein using Proteinase K (Roche). The DNA was purified
648 using phenol chloroform extraction then treated with RNAse A. DNA was quantified using
649 Qubit DNA HS (Invitrogen). ChIP-seq libraries were prepared using NEBNext ChIP-Seq Library
650 Prep (New England Biolabs). Sequencing was performed using HiSeq 2500 (Illumina Inc) with 40
651 BP single end reads.

652

653

654 **Native ChIP**

655 The crosslinking protocol described above was performed for all antibodies in Table 1,
656 except the H2Aubi119 antibody where native ChIP was used. The protocol for native ChIP has
657 previously been described (Hasegawa et al., 2016). In brief, cell lysate from fresh frozen GNPs
658 or MB was incubated in MNase for 20 min at 4°C and stopped by adding 1/25 0.5 M EDTA. The
659 amount of MNase used for each reaction was batch adjusted to obtain mono-nucleosomes
660 after a 20 min digestion. After centrifugation at 13000 rpm for 15 min at 4C, the supernatant
661 containing the mononucleosome fraction was collected. Protein was precipitated using Protein
662 G Dynabeads (Invitrogen), with rabbit anti-IgM IgG linker antibodies for the H2Aubi119 ChIP.
663 The beads were washed 3 times using buffers described in Hasegawa et al (2016). DNA was
664 eluted, freed from protein using Proteinase K (Roche), and purified using phenol chloroform
665 extraction. Preparation of ChIP-seq libraries was performed as described for crosslinking ChIP.

666 *Table 1*: Antibodies and concentrations used for ChIP

| **Antibody** | **Vendor** | **Species** | **Serotype** | **Catalog** | **Amount (ug, ul) in 750 ul lysate** | **RRID** |
|---|---|---|---|---|---|---|
| H3K4me3 | Abcam | Rabbit polyclonal | IgG | ab8580 | 5 ug | *AB_306649* |
| H3K4me1 | Abcam | Rabbit polyclonal | IgG | ab8895 | 5 ug | *AB_306847* |
| H3K27me3 | Milipore | Rabbit polyclonal | IgG | 07-449 | 5 ug | *AB_310624* |
| H3K27ac | Abcam | Rabbit polyclonal | IgG | ab4729 | 5 ug | *AB_2118291* |
| Ring1b | Active Motif | Rabbit monoclonal | IgG | 39664 | 10 ul | *AB_2615006* |
| H2Aubi119 | Milipore (Upstate) | Mouse monoclonal | IgM | 05-678 | 10 ug | *AB_309899* |
| H3K36me3 | Abcam | Rabbit polyclonal | IgG | ab9050 | 5 ug | *AB_306966* |
| RNA polymerase 2 (S5 phospho) | Abcam | Rabbit polyclonal | IgG | ab5131 | 5 ug | *AB_449369* |
| RNA polymerase 2 (S5 phospho) | Active Motif | Mouse monoclonal | IgG | 39097 | 10 ul | *AB_2732926* |

667

668

669 **ChIP-seq data processing**

670 Reads were adaptor filtered, trimmed, mapped to mm9 using Bowtie2. From the mapped
671 reads duplicates and reads with a mapping quality below 20 were discarded. Quantification of
672 a region around the TSS which were defined in the previous section proceeded with the
673 following steps. Peaks in aligned reads for histone modifications were called using EPIC
674 (https://github.com/biocore-ntnu/epic), which is a more computationally efficient version of
675 SICER (*116*). Macs2 (*117*) was used to call peaks for the ATAC-seq data as no input sequencing
676 was done. Many of the histone modifications would vary substantially in terms of both the
677 number of reads in a set genomic region but also in terms of the width of the marked area. To
678 capture the variation in with the promoter modifications were quantified, for each of the
679 annotated transcriptional start sites (TSSs) with a window of 250 base pairs flanking the site
680 was quantified and extended to include overlapping peaks. All quantified promoter features
681 underwent a regularized log transform (*118*) and were scaled 0 to 1.

682 For RNAseq and H3K36me3 we altered our quantification strategy. H3K36me3 is a histone
683 modification associated with an elongating RNA polymerase II seem during active expression,
684 which is absent over the promoter. The H3K36me3 ChIP-seq was quantified across the entire
685 gene body and then divided by the length of the gene. The P7 RNAseq data was quantified
686 across all exons and divided by the total length of the exons. Both RNAseq and H3K36me3
687 were then scaled between 0 and 1.

688 To calculate the enrichment of chromatin modifications, epigenetic features were
689 separated based upon the distribution of the quantified modifications. The normalized data

690 show a clearly bimodal distribution or a distribution with a large upper tail**.** Marked or bound
691 versus unmarked or unbound genes could be distinguished by fitting two normal distributions.
692 First long upper tails were removed by calculating the first order derivative of the smoothed
693 ranked data similar to how super enhancers are identified (*42*). We set the threshold for the
694 long upper tails at 0.0004 pragmatically. The remainder of the datapoints for each tracks were
695 split using a mixture of Gaussian distributions using mixtools (*119*). Each data set were split
696 into marked/unmarked/tail for the enrichment calculation and for plotting.

697 **RNA-seq**

698 RNA was extracted using Trizol (Invitrogen), with and mechanical disruption with a 1.5 ul
699 tube mortise and pestle. Following precipitation, the RNA was treated with DNase1 and
700 cleaned up with a RNAeasy colomn (Qiagen). RNA was quantified with the Qubit and the
701 quality of the RNA was assayed using Agilent Bioanalyzer. Libraries were prepared using mRNA
702 purified using polyA bead selection (New England Biolabs), using Illumina TruSeq v2 library
703 preparation kit (Illumina). Sequencing was performed using HiSeq 2500 with 100 BP single-end
704 to approximately 60-70 million reads per sample.

705 **Generating cell type-specific transcript models**

706 Since we were attempting to identify epigenetic regulatory features by looking for common
707 signatures present in a large number of genes, it was important that each protein coding gene
708 would be counted roughly equally. Some genes have numerous annotated TSS while others
709 only have one and the discrepancy could bias the downstream analysis. We wanted to
710 represent each protein coding gene with at least one TSS and one transcript model but

711 permitted a gene to have multiple TSS and associated transcript models if there was evidence in
712 the ChIP-seq data of an additional TSS. We used both the Ensembl mouse 67 annotation
713 system as well as the UCSC mm9 knownGene annotation to generate a robust list of baseline
714 TSSs and transcript models. The TSS in the reference annotation was quantified using both the
715 GNP H3K4me3 data and the adult cerebellum H3K4me3 data from the Encode project (*120*).
716 For genes with clear H3K4me3 binding we selected transcripts with the strongest H3K4me3 at
717 the TSS or within 500 BP of the optimal TSS. For genes without clear H3K4me3 over any
718 transcript we took the maximum of all of the other modifications annotated over potential TSS.
719 To identify the best transcript model for each gene from the numerous in the reference
720 transcriptome we performed de-novo transcript assembly from 1 replicate in each of the time
721 points in the RNA-seq data using Stringtie (*121*). The time point transcript assemblies were
722 then merged using Stringtie merge without the reference annotation. Both selecting a TSS and
723 transcript model using only de novo assembly is complicated by a number of issues. The PolyA
724 selection is 3' biased, which will bias the de novo transcript models towards TSS which occur in
725 the 3' direction in a manner that is worse for low expressed genes. We calculated an overlap
726 for each transcript between the reference transcript library (UCSC and ensemble) and the
727 Stringtie models using Bedtools (*122*). We then selected a transcript model from the reference
728 with the highest overlap to the Stringtie models for each gene.

729 **RNAseq quantification**

730 The RNAseq data was mapped to mm9 using Tophat2 (*123*), so the last mm9 associated
731 Ensembl release (release 67) was used as reference transcriptome. The transcript models used
732 to quantify the RNAseq data developed as described above. Transcripts were quantified with

733 HTSEQ. The overall pipeline was developed with modification from the Bradner lab pipeline
734 (https://github.com/BradnerLab/pipeline).

735 **Processing existing data sets**

736 The Hatten lab NeuroD1-TRAP data was downloaded from GEO (GSE74400) and the
737 Affemetrix annotations linked to the Ensembl mouse 67 transcript models were downloaded
738 using biomaRt. Initial analysis was performed using oligo and limma packages from
739 Bioconductor. The probes were then collapsed to the transcript models described above.

740 The scRNAseq data from the Taylor lab was obtained from GEO (*31*) and the reads were
741 processed using the DropletUtils package from Bioconductor. We used the annotated cluster
742 to cell tables provided in the supplementary data to reconstruct the data. The granule neuron
743 lineages were separated from other cell types like Purkinje cells, astrocytes. In order to
744 eliminate genes from the bulk RNAseq that were likely arising from non-granule neuron lineage
745 we used the existing cell type clustering analysis done by the Taylor lab using Seurat. The cell
746 types were separated into granule neuron lineage and non GN lineage. For each gene, across
747 the cell types, the highest expression in GN lineage and the non GN lineage cells was calculated.
748 By comparing the maximum GN expression to non GN expression we excluded genes with the
749 following 3 criteria. We excluded genes that were expressed in alternative lineages when not
750 expressed at all in the GN lineage cells, genes that were 2 fold higher in non GN or when they
751 were significantly higher expressed in non GN lineage by the Taylor lab Seurat analysis.

752

753 **Differentiation gene classification**

754 Expression cutoffs for transcriptional time course data were established using the
755 distribution of the maximal values from the time course. For each dataset the average
756 maximum of the 3 highest expressed timepoints/replicates were taken. Based upon the
757 distribution we created a mixture model to estimate the point at which the probability of the
758 expressed versus unexpressed distribution was equal to .50. For the Scott lab RNAseq dataset
759 the count data was highly zero weighted, so we utilized a mixture of 2 gamma distributions
760 (*124*). The Hatten lab TRAP data was modeled using 2 normal distributions. The transcriptional
761 profiles were merged by interpolating the overlapping time points. We then calculated the
762 timepoint that had the maximum and minimum RNA using the combined dataset. Using the
763 maximum and minimum values we calculated a fold change using both datasets. We also
764 estimated the developing time point at which the gene reached 50% of its maximum transcript
765 abundance (t50). In order to be accepted as a significant changer p-values were calculated
766 based upon each dataset individually, using DEseq2 (*118*) for the RNAseq dataset and limma
767 (*125*) for the TRAP data.

768 **Mouse husbandry**

769 Ezh2 conditional knockout (Math1$^{Cre;}$ *Ezh2*$^{flox/flox}$ ) mice were generated by crossing
770 Math1>Cre (*56*) with the *Ezh2*$^{flox/flox}$ mouse where Loxp sites flank the catalytic SET domain of
771 Ezh2 (*55*). Mice were then bred homozygous for the flox Ezh2 allele, and Cre negative
772 littermates were used for controls. Math1>GFP (*30*) mice were maintained as homozygous.
773 Math1$^{Cre;}$ *Ezh2*$^{flox/flox}$;Math1>GFP mice All animal studies were approved by the Stanford APLAC
774 review board protocol .

775 **Spontaneous MB tumor formation**

776 ChIPseq and RNAseq data was generated from spontaneous MBs that occurred in Ptch1$^{+/-}$

777 mice, with MB formation determined by following for neurologic decline. Since the generation

778 of MBs can have severe neurological affects, animals were monitored daily for physical

779 abnormalities such as ataxia, hunching, immobility. Math1$^{Cre;}$ *Ezh2*$^{flox/flox}$;Ptch1$^{+/-}$ and

780 *Ezh2*$^{flox/flox}$;Ptch1$^{+/-}$ mice were also generated to test the effect of *Ezh2* cKO on MB formation.

781 *Table 2*: Mice alleles used

| **Allele** | **RRID** |
|---|---|
| Math1-Cre | IMSR_JAX:011104 |
| *Ezh2*$^{flox}$ | MMRRC_015499-UNC |
| Math1-GFP | MGI:4456122 |
| Ptch1+/- | IMSR_JAX:003081 |

782

783 **Edu pulse/chase**

784 To assess migration of the GNPs out of the EGL we performed 48 h Edu pulse chase. A single

785 IP injection (50mg/kg using a 5mg/mL stock diluted in PBS) was administered to p5 *Ezh2* cKO

786 and wild-type mice. After 48 h, brains were dissected and fixed in 4% PFA overnight then

787 transferred into 30% sucrose for 24h. Fixed whole cerebellum were mounted in OCT and

788 sectioned at 20µm. EdU staining was performed as per manufacturers instructions (Life

789 Technologies, Clik-iT Plus EdU Alexa Fluor 647 Imaging Kit, cat no. C10640). Following Edu
790 labeling, sections were blocked in 0.2% triton X-100 and 5% Donkey serum 1h at RT. Sections
791 were then stained with Rabbit anti-p27 as described in the tissue immunofluorescence section.

792 **GNP isolation and purification**

793 The GNP extraction and purification has been previously described (*1, 126*). In brief, the
794 mice were euthanized and the cerebella were dissected and minced. The cerebellar pieces
795 were incubated with 10 U/ml papain (Worthington, NJ, United States, LSOO3126) and 250 U/ml
796 DNase (Sigma, MO, United States, D4627) in HBSS (Stem Cell Technologies Canada Inc,
797 Vancouver, Canada, 37150) at 37 C for 30 min and the papain was halted using 8 mg/ml
798 Ovomucoid (Sigma, MO, United States, T2011) and 8 mg/ml bovine serum albumin (Sigma).
799 The pieces were then sequentially triturated in the presence of DNase to prevent clumping,
800 then passed through a 70uM nylon cell strainer (VWR, 21,008-952). GNPs were isolated using a
801 35%, 65% Percoll (Sigma, P4937) step gradient with centrifugation at 2500 rpm for 15 min.

802 **E15.5 GNP purification**

803 Because of the small cell number and the contamination of Sox2 + cells we utilized FACS to
804 purify the pre-Shh GNPs. Timed pregnant mothers homozygous for the *Math1*-GFP reporter
805 were sacrificed using cervical dislocation following deep anesthesia. The embryos were
806 harvested, and the rhombic lip and cerebellar anlage were dissected using micro-scissors and
807 jeweller forceps. The single cell suspension was generated as above. GFP+ were isolated using
808 standard FACS technique. The cells were then lyzed in Trizol without centrifugation and RNA
809 purification proceeded immediately.

810 **MB cell culture**

811 MB cell lines (*61*) generated from *Ptch1*$^{+/-}$ mice by the Seghal Lab (Dana-Farber Cancer
812 Institute, Harvard Medical School), and *Ptch1*$^{+/-}$; *Tpr53*$^{-/-}$ from the Rudin Lab (Memorial Sloan
813 Kettering Cancer Center), were grown as suspension as neurospheres. Briefly, cells were
814 maintained in DMEM/F12 supplemented with glutamine and with B27 minus vitamin A,
815 penicillin and streptomycin. The cells were passaged every 6 days by collecting the spheres by
816 gravity, washing, followed by dissociation with Accutase (Stemcell Technologies 07920) and
817 replating as a suspension to allow cells to spontaneously re-aggregate. UNC1999 was soluble in
818 DMSO while Palbociclib was soluble in water (Selleckchem).

819 **GNP culture**

820 P7 GNPs were purified as described above. The cerebella dissected either from the *Ezh2*
821 cKO described above or from mice with a Math1>GFP (*30*) reporter that delineates transit
822 amplifying GNPs from differentiated cells. The GNPs were grown as described previously for
823 our GNP proliferation conditions (*1*) with 3ng/ml of Shh 461-54 (R&D systems). The cells were
824 fixed at 24 h and immunofluorescence imaging occurred. To measure the protein abundance
825 of the product from the differentiation genes, the freshly isolated cells were plated without Shh
826 to induce differentiation, fixed after 6h, 24h or 48h in culture.

827 **Cell culture imaging**

828 All cell culture imaging for both GNPs and MB cells was performed on 96 well, glass bottom
829 plates (Cellvis P96-1.5H-N). The plates were coated with 100 ug/ml PDL (Millipore A-003-E) for
830 3 h at 37 C, then washed, and coated with 10 ug/ml Lamnin (Millipore CC095) overnight at 37 C.
831 GNPs were purified as described above and MB cells were dissociated with Accutase as

832 described above, then filtered using a 70-micron to remove clusters of cells. Following cell
833 counting 10,000 cells were plated per well and perturbations were performed 2h after plating.
834 Following treatment, the cells were fixed with 4% paraformaldehyde for 10 min at room
835 temperature. The cells were then blocked using 5% donkey serum, 1% BSA and 0.2% triton X-
836 100 for 1h at room temperature. Primary antibodies were incubated overnight at 4 C. The
837 primary antibodies used are described in table 3. Cells were co-stained with Rhodamine
838 Phalloidin (Molecular Probes R415). Donkey anti IgG secondary antibodies against mouse and
839 rabbit were used conjugated to Alexa-488 and Alexa-647 at 1:500 (Jackson Immunoresearch).
840 All cell imaging was performed using the ImageXpress Micro XLS Widefield High Content
841 Screening System (Molecular Devices, Sunnyvale, CA) using 20x (0.75 NA) Nikon objectives. The
842 intensity of fluorescence in each cell was automatically calculated using custom MATLAB
843 scripts. Nuclei were segmented using DAPI as previously described (*127*). Downstream analysis
844 was performed in R.

845

846 *Table 3*: Antibodies used for immunofluorescence

| Antibody | Vendor | Species | Serotype | Catalog | Dilution | RRID |
|---|---|---|---|---|---|---|
| NeuN | Millipore | mouse monoclonal | IgG | MAB377 | 1:200 | AB_2298772 |
| Phospho-Rb (Ser807/811) clone D20B12 | Cell Signaling Technology | rabbit monoclonal | IgG | 8516 | 1:1000 | AB_11178658 |
| p27 | Abcam | Rabbit monoclonal | IgG | ab32034 | 1:100 | AB_2244732 |
| Cbx7 | Abcam | Rabbit polyclonal | IgG | ab21873 | 1:200 | AB_726005 |
| H3K27me3 | Active Motif | Rabbit polyclonal | IgG | 39155 | 1:200 | AB_2561020 |
| Map2 | Abcam | Chicken polyclonal | IgG | ab5392 | 1:2500 | AB_2138153 |
| Ezh2 clone D2C9 | Cell Signaling Technology | Rabbit monoclonal | IgG | 5246 | 1:200 | AB_10694683 |

847 **Tissue Immunofluorescence**

848 P7 mice were perfused with 4% PFA, then fixed for 16 h. Fixed whole cerebellum were
849 mounted in OCT and sectioned at 20µm. Antigen retrieval was performed only for Cbx7 using
850 10 mM Citrate pH 6 buffer, boiled for 15 min. Immunofluorescence proceeded as described in
851 the cell culture staining protocol. Panoramic Imaging was done on a Zeiss Axioimager and 40x
852 confocal micrographs were generated using a Leica Sp2 confocal microscope.

853 **Cerebellar layer segmentation**

854 To segment the cerebellum into outer EGL, inner EGL, ML, IGL and deep white matter we
855 generated panoramic tiled immunofluorescence images of the P7 cerebellum, with DAPI, NeuN
856 (Alexa 488) and p27 (Alexa 647). The images were then background corrected and stitched in
857 Fiji (Image J) using Grid/Collection with 20% overlap. A custom MATLAB script was then used to

858 perform the segmentation. The first pass performed preprocessing on the image and coarsely
859 identified each layer using a combination or ratio of the individual channels. The IGL was
860 defined as NeuN high, the inner EGL as p27 high, and the outer EGL as DAPI high. Each layer of
861 the cerebellum borders the following layer, allowing previously established layers to serve as
862 guides for the development of following layers. Beginning from the inner most layer, through
863 to the outermost, dilations were used to define and fill out the regions of interest. The pixels of
864 each region were filtered and smoothed to promote clear boundaries between the layers. A
865 composite image was then produced containing all the regions. With each region clearly
866 defined, calculations for segmented pixel area and region measurements for NeuN, P27, and
867 DAPI fluorescence intensity for each layer could be determined.

868 **Cerebellar immunofluorescence quantification**

869 The images were generated as described above. Linear segments centered along the pia,
870 with an EGL on either side were selected and made into separate images. The image segments
871 were further subdivided into 200 pixel sections moving perpendicular to the axis of the EGL. A
872 line track was generated by taking the pixel mean perpendicular to the EGL. The individual line
873 segments were then aligned using cross-correlation from the Stats package in R. After
874 alignment the symmetric line segment was split by calculating the local minimum near the
875 center of the dataset for an average p27 intensity of the entire dataset. The center was set to 0
876 on the x-axis which allowed us to split each line segment into 2 moving from 0 the pial
877 boundary to the IGL at the highest values. There was variability in the distance from the center
878 point to the pial boundary where the EGL starts caused by a gap in the arachnoid along the
879 invagination of the folia. The pial boundary was determined as a drop off in the

880 immunofluorescence background. To find this boundary we identified the peak change in the
881 product of NeuN and p27 values.

882 **Quantification of cell cycle and differentiation and process extension**

883 Dead cells and G2 cells were separated from G0/1 cells using the cell pixel area and DAPI
884 median values, then G0, G1 and G2 were further separated according to the level of Ki67 or RB
885 phosphorylation (Ser807/811). Differentiated cells were identified using a cut-off value for
886 NeuN immunofluorescence only accepting differentiating cells if they are marked as G0 by the
887 above-described criteria. Process extension and process length was quantified using
888 Neuroncyto 2 (*60*) image by image using Map2 immunofluorescence with DAPI labeling of the
889 nuclei.

890

891

892 # Additional information

893 **Data availability and resource sharing**

894 Data supporting this study are available in GEO GSE279346 and GSE279347. Custom
895 analysis scripts are available following GITHUB repositories; jpurzner/seq_pipelines,
896 jpurzner/chip_tools, jpurzner/cell_culture_segment, jpurzner/layer_quant,
897 jpurzner/cerebellar_segmentation.

898 **Acknowledgements**

899 The research presented here was funded by the National Institute Health (5R01CA157895-
900 02 ), the American Brain Tumour Association, B*CURED and the American Association of
901 Neurologic Surgeons via the Neurosurgery Research and Education Fund.

902 **Author contributions**

903 JP, ASB, TP, KW, MDT, YJT, MTF, MPS designed research. JP, ASB, TP, LE, SB, UL, AK, KW
904 performed research. JP, ASB, TP, KA, AS, KW, MDT, YJT, MTF, MPS analyzed data. JP, TP, ASB
905 and MPS wrote the paper.

906 **Conflicts of interest**

907 The authors declare no conflicts of interest.

908 # References


909 1. R. J. Wechsler-Reya, M. P. Scott, Control of neuronal precursor proliferation in the
910 cerebellum by Sonic Hedgehog. *Neuron* **22**, 103-114 (1999).
911 2. P. M. Lewis, A. Gritli-Linde, R. Smeyne, A. Kottmann, A. P. McMahon, Sonic hedgehog
912 signaling is required for expansion of granule neuron precursors and patterning of the
913 mouse cerebellum. *Dev Biol* **270**, 393-410 (2004).
914 3. V. A. Wallace, Purkinje-cell-derived Sonic hedgehog regulates granule neuron precursor
915 cell proliferation in the developing mouse cerebellum. *Current biology : CB* **9**, 445-448
916 (1999).
917 4. A. M. Kenney, M. D. Cole, D. H. Rowitch, Nmyc upregulation by sonic hedgehog signaling
918 promotes proliferation in developing cerebellar granule neuron precursors.
919 *Development* **130**, 15-28 (2003).
920 5. A. M. Kenney, D. H. Rowitch, Sonic hedgehog promotes G(1) cyclin expression and
921 sustained cell cycle progression in mammalian neuronal precursors. *Mol Cell Biol* **20**,
922 9055-9067 (2000).
923 6. Z. J. Yang *et al.*, Medulloblastoma can be initiated by deletion of Patched in lineage-
924 restricted progenitors or stem cells. *Cancer cell* **14**, 135-145 (2008).
925 7. V. Ramaswamy, C. Nor, M. D. Taylor, p53 and Meduloblastoma. *Cold Spring Harbor*
926 *perspectives in medicine* **6**, (2015).
927 8. N. Zhukova *et al.*, Subgroup-specific prognostic implications of TP53 mutation in
928 medulloblastoma. *Journal of clinical oncology : official journal of the American Society of*
929 *Clinical Oncology* **31**, 2927-2935 (2013).
930 9. F. M. G. Cavalli *et al.*, Intertumoral Heterogeneity within Medulloblastoma Subgroups.
931 *Cancer cell* **31**, 737-754 e736 (2017).
932 10. M. Kool *et al.*, Genome sequencing of SHH medulloblastoma predicts genotype-related
933 response to smoothened inhibition. *Cancer cell* **25**, 393-405 (2014).
934 11. D. J. Mabbott, L. Penkman, A. Witol, D. Strother, E. Bouffet, Core neurocognitive
935 functions in children treated for posterior fossa tumors. *Neuropsychology* **22**, 159-168
936 (2008).
937 12. D. J. Mabbott *et al.*, Serial evaluation of academic and behavioral outcome after
938 treatment with cranial radiation in childhood. *Journal of clinical oncology : official*
939 *journal of the American Society of Clinical Oncology* **23**, 2256-2263 (2005).
940 13. L. Dirven *et al.*, Neurocognitive functioning and health-related quality of life in adult
941 medulloblastoma patients: long-term outcomes of the NOA-07 study. *Journal of neuro-*
942 *oncology* **148**, 117-130 (2020).
943 14. C. G. Eberhart, W. E. Kaufman, T. Tihan, P. C. Burger, Apoptosis, neuronal maturation,
944 and neurotrophin expression within medulloblastoma nodules. *Journal of*
945 *neuropathology and experimental neurology* **60**, 462-469 (2001).
946 15. P. C. Burger, F. C. Grahmann, A. Bliestle, P. Kleihues, Differentiation in the
947 medulloblastoma. A histological and immunohistochemical study. *Acta*
948 *neuropathologica* **73**, 115-123 (1987).

949 16. R. T. Meurer *et al.*, Immunohistochemical expression of markers Ki-67, neun,
950 synaptophysin, p53 and HER2 in medulloblastoma and its correlation with
951 clinicopathological parameters. *Arquivos de neuro-psiquiatria* **66**, 385-390 (2008).
952 17. H. Zhao, O. Ayrault, F. Zindy, J. H. Kim, M. F. Roussel, Post-transcriptional down-
953 regulation of Atoh1/Math1 by bone morphogenic proteins suppresses medulloblastoma
954 development. *Genes Dev* **22**, 722-727 (2008).
955 18. I. Rios, R. Alvarez-Rodriguez, E. Marti, S. Pons, Bmp2 antagonizes sonic hedgehog-
956 mediated proliferation of cerebellar granule neurones through Smad5 signalling.
957 *Development* **131**, 3159-3168 (2004).
958 19. J. S. Espinosa, L. Luo, Timing neurogenesis and differentiation: insights from quantitative
959 clonal analyses of cerebellar granule cells. *J Neurosci* **28**, 2301-2312 (2008).
960 20. T. Kim, H. Park, K. Tanaka-Yamamoto, Y. Yamamoto, Developmental timing-dependent
961 organization of synaptic connections between mossy fibers and granule cells in the
962 cerebellum. *Commun Biol* **6**, 446 (2023).
963 21. J. K. Rhee, H. Park, T. Kim, Y. Yamamoto, K. Tanaka-Yamamoto, Projection-dependent
964 heterogeneity of cerebellar granule cell calcium responses. *Molecular brain* **14**, 63
965 (2021).
966 22. S. A. Shuster *et al.*, The relationship between birth timing, circuit wiring, and
967 physiological response properties of cerebellar granule cells. *Proc Natl Acad Sci U S A*
968 **118**, (2021).
969 23. K. Leto *et al.*, Consensus Paper: Cerebellar Development. *Cerebellum*, (2015).
970 24. A. Chedotal, Should I stay or should I go? Becoming a granule cell. *Trends Neurosci* **33**,
971 163-172 (2010).
972 25. X. Zhu *et al.*, Role of Tet1/3 Genes and Chromatin Remodeling Genes in Cerebellar
973 Circuit Formation. *Neuron* **89**, 100-112 (2016).
974 26. P. Skowron *et al.*, The transcriptional landscape of Shh medulloblastoma. *Nature*
975 *communications* **12**, 1749 (2021).
976 27. A. Shearn, G. Hersperger, E. Hersperger, Genetic analysis of two allelic temperature-
977 sensitive mutants of Drosophila melanogaster both of which are zygotic and maternal-
978 effect lethals. *Genetics* **89**, 341-353 (1978).
979 28. E. A. Carrington, R. S. Jones, The Drosophila Enhancer of zeste gene encodes a
980 chromosomal protein: examination of wild-type and mutant protein distribution.
981 *Development* **122**, 4073-4083 (1996).
982 29. D. C. Tkachuk, S. Kohler, M. L. Cleary, Involvement of a homolog of Drosophila trithorax
983 by 11q23 chromosomal translocations in acute leukemias. *Cell* **71**, 691-700 (1992).
984 30. E. A. Lumpkin *et al.*, Math1-driven GFP expression in the developing nervous system of
985 transgenic mice. *Gene expression patterns : GEP* **3**, 389-395 (2003).
986 31. M. C. Vladoiu *et al.*, Childhood cerebellar tumours mirror conserved fetal transcriptional
987 programs. *Nature* **572**, 67-73 (2019).
988 32. R. Machold, C. Klein, G. Fishell, Genes expressed in Atoh1 neuronal lineages arising from
989 the r1/isthmus rhombic lip. *Gene expression patterns : GEP* **11**, 349-359 (2011).
990 33. D. Morales, M. E. Hatten, Molecular markers of neuronal progenitors in the embryonic
991 cerebellar anlage. *J Neurosci* **26**, 12226-12236 (2006).

992 34. R. Cao *et al.*, Role of histone H3 lysine 27 methylation in polycomb-group silencing.
993 *Science* **298**, 1039-1043 (2002).
994 35. H. B. Wang *et al.*, Role of histone H2A ubiquitination in polycomb silencing. *Nature* **431**,
995 873-878 (2004).
996 36. T. Rauch, G. P. Pfeifer, Methylated-CpG island recovery assay: a new technique for the
997 rapid detection of methylated-CpG islands in cancer. *Laboratory investigation; a journal*
998 *of technical methods and pathology* **85**, 1172-1180 (2005).
999 37. M. P. Creyghton *et al.*, Histone H3K27ac separates active from poised enhancers and
1000 predicts developmental state. *Proc Natl Acad Sci U S A* **107**, 21931-21936 (2010).
1001 38. A. Rada-Iglesias *et al.*, A unique chromatin signature uncovers early developmental
1002 enhancers in humans. *Nature* **470**, 279-283 (2011).
1003 39. N. D. Heintzman *et al.*, Histone modifications at human enhancers reflect global cell-
1004 type-specific gene expression. *Nature* **459**, 108-112 (2009).
1005 40. N. D. Heintzman *et al.*, Distinct and predictive chromatin signatures of transcriptional
1006 promoters and enhancers in the human genome. *Nat Genet* **39**, 311-318 (2007).
1007 41. J. D. Buenrostro, B. Wu, H. Y. Chang, W. J. Greenleaf, ATAC-seq: A Method for Assaying
1008 Chromatin Accessibility Genome-Wide. *Curr Protoc Mol Biol* **109**, 21 29 21-29 (2015).
1009 42. W. A. Whyte *et al.*, Master transcription factors and mediator establish super-enhancers
1010 at key cell identity genes. *Cell* **153**, 307-319 (2013).
1011 43. R. Margueron, D. Reinberg, The Polycomb complex PRC2 and its mark in life. *Nature*
1012 **469**, 343-349 (2011).
1013 44. A. Hugues, C. S. Jacobs, F. Roudier, Mitotic Inheritance of PRC2-Mediated Silencing:
1014 Mechanistic Insights and Developmental Perspectives. *Frontiers in plant science* **11**, 262
1015 (2020).
1016 45. U. Jadhav *et al.*, Replicational Dilution of H3K27me3 in Mammalian Cells and the Role of
1017 Poised Promoters. *Mol Cell* **78**, 141-151 e145 (2020).
1018 46. R. T. Coleman, G. Struhl, Causal role for inheritance of H3K27me3 in maintaining the OFF
1019 state of a Drosophila HOX gene. *Science* **356**, (2017).
1020 47. P. Asp *et al.*, Genome-wide remodeling of the epigenetic landscape during myogenic
1021 differentiation. *Proc Natl Acad Sci U S A* **108**, E149-158 (2011).
1022 48. D. S. Gilmour, J. T. Lis, RNA polymerase II interacts with the promoter region of the
1023 noninduced hsp70 gene in Drosophila melanogaster cells. *Mol Cell Biol* **6**, 3984-3989
1024 (1986).
1025 49. D. J. Huebert, M. Kamal, A. O'Donovan, B. E. Bernstein, Genome-wide analysis of histone
1026 modifications by ChIP-on-chip. *Methods* **40**, 365-369 (2006).
1027 50. T. S. Mikkelsen *et al.*, Genome-wide maps of chromatin state in pluripotent and lineage-
1028 committed cells. *Nature* **448**, 553-560 (2007).
1029 51. N. P. Blackledge *et al.*, Variant PRC1 complex-dependent H2A ubiquitylation drives PRC2
1030 recruitment and polycomb domain formation. *Cell* **157**, 1445-1459 (2014).
1031 52. M. Ku *et al.*, Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of
1032 bivalent domains. *PLoS Genet* **4**, e1000242 (2008).
1033 53. E. Vire *et al.*, The Polycomb group protein EZH2 directly controls DNA methylation.
1034 *Nature* **439**, 871-874 (2006).

1035 54. D. O'Carroll *et al.*, The polycomb-group gene Ezh2 is required for early mouse
1036 development. *Mol Cell Biol* **21**, 4330-4336 (2001).
1037 55. I. H. Su *et al.*, Ezh2 controls B cell development through histone H3 methylation and Igh
1038 rearrangement. *Nat Immunol* **4**, 124-131 (2003).
1039 56. V. Matei *et al.*, Smaller inner ear sensory epithelia in Neurog 1 null mice are related to
1040 earlier hair cell cycle exit. *Dev Dyn* **234**, 633-650 (2005).
1041 57. J. Muller *et al.*, Histone methyltransferase activity of a Drosophila Polycomb group
1042 repressor complex. *Cell* **111**, 197-208 (2002).
1043 58. S. Erhardt *et al.*, Consequences of the depletion of zygotic and embryonic enhancer of
1044 zeste 2 during preimplantation mouse development. *Development* **130**, 4235-4248
1045 (2003).
1046 59. R. Margueron *et al.*, Ezh1 and Ezh2 maintain repressive chromatin through different
1047 mechanisms. *Mol Cell* **32**, 503-518 (2008).
1048 60. K. H. Ong, J. De, L. Cheng, S. Ahmed, W. Yu, NeuronCyto II: An automatic and
1049 quantitative solution for crossover neural cells in high throughput screening. *Cytometry.*
1050 *Part A : the journal of the International Society for Analytical Cytology* **89**, 747-754
1051 (2016).
1052 61. X. Zhao *et al.*, RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and
1053 Tumor Evolution in Shh Pathway-Dependent Tumors. *Cancer research* **75**, 3623-3635
1054 (2015).
1055 62. K. D. Konze *et al.*, An orally bioavailable chemical probe of the Lysine Methyltransferases
1056 EZH2 and EZH1. *ACS chemical biology* **8**, 1324-1334 (2013).
1057 63. D. W. Fry *et al.*, Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and
1058 associated antitumor activity in human tumor xenografts. *Molecular cancer therapeutics*
1059 **3**, 1427-1438 (2004).
1060 64. L. V. Goodrich, L. Milenkovic, K. M. Higgins, M. P. Scott, Altered neural cell fates and
1061 medulloblastoma in mouse patched mutants. *Science* **277**, 1109-1113 (1997).
1062 65. T. G. Oliver *et al.*, Loss of patched and disruption of granule cell development in a pre-
1063 neoplastic stage of medulloblastoma. *Development* **132**, 2425-2439 (2005).
1064 66. T. Purzner *et al.*, Developmental phosphoproteomics identifies the kinase CK2 as a
1065 driver of Hedgehog signaling and a therapeutic target in medulloblastoma. *Sci Signal* **11**,
1066 (2018).
1067 67. K. Matlik, E. E. Govek, M. R. Paul, C. D. Allis, M. E. Hatten, Histone bivalency regulates
1068 the timing of cerebellar granule cell development. *Genes Dev* **37**, 570-589 (2023).
1069 68. V. Ramesh, F. Liu, M. S. Minto, U. Chan, A. E. West, Bidirectional regulation of
1070 postmitotic H3K27me3 distributions underlie cerebellar granule neuron maturation
1071 dynamics. *eLife* **12**, (2023).
1072 69. X. Feng *et al.*, Polycomb Ezh2 controls the fate of GABAergic neurons in the embryonic
1073 cerebellum. *Development* **143**, 1971-1980 (2016).
1074 70. C. Mozzetta *et al.*, Selective control of Pax7 expression by TNF-activated
1075 p38alpha/polycomb repressive complex 2 (PRC2) signaling during muscle satellite cell
1076 differentiation. *Cell Cycle* **10**, 191-198 (2011).

1077 71. A. H. Juan *et al.*, Polycomb EZH2 controls self-renewal and safeguards the transcriptional
1078 identity of skeletal muscle stem cells. *Genes Dev* **25**, 789-794 (2011).
1079 72. G. Caretti, M. Di Padova, B. Micales, G. E. Lyons, V. Sartorelli, The Polycomb Ezh2
1080 methyltransferase regulates muscle gene expression and skeletal muscle differentiation.
1081 *Genes Dev* **18**, 2627-2638 (2004).
1082 73. A. He *et al.*, Polycomb repressive complex 2 regulates normal development of the
1083 mouse heart. *Circulation research* **110**, 406-415 (2012).
1084 74. X. P. Yang *et al.*, EZH2 is crucial for both differentiation of regulatory T cells and T
1085 effector cell expansion. *Scientific reports* **5**, 10643 (2015).
1086 75. B. P. Coe *et al.*, Genomic deregulation of the E2F/Rb pathway leads to activation of the
1087 oncogene EZH2 in small cell lung cancer. *PLoS One* **8**, e71670 (2013).
1088 76. A. P. Bracken *et al.*, EZH2 is downstream of the pRB-E2F pathway, essential for
1089 proliferation and amplified in cancer. *Embo J* **22**, 5323-5335 (2003).
1090 77. R. Wijayatunge *et al.*, The histone demethylase Kdm6b regulates a mature gene
1091 expression program in differentiating cerebellar granule neurons. *Mol Cell Neurosci* **87**,
1092 4-17 (2018).
1093 78. A. H. Cleveland *et al.*, PRC2 disruption in cerebellar progenitors produces cerebellar
1094 hypoplasia and aberrant myoid differentiation without blocking medulloblastoma
1095 growth. *Acta neuropathologica communications* **11**, 8 (2023).
1096 79. K. Jun *et al.*, Ablation of P/Q-type Ca(2+) channel currents, altered synaptic
1097 transmission, and progressive ataxia in mice lacking the alpha(1A)-subunit. *Proc Natl*
1098 *Acad Sci U S A* **96**, 15245-15250 (1999).
1099 80. H. Komuro, P. Rakic, Modulation of neuronal migration by NMDA receptors. *Science* **260**,
1100 95-97 (1993).
1101 81. M. Farrant, D. Feldmeyer, T. Takahashi, S. G. Cull-Candy, NMDA-receptor channel
1102 diversity in the developing cerebellum. *Nature* **368**, 335-339 (1994).
1103 82. D. J. Rossi, N. T. Slater, The developmental onset of NMDA receptor-channel activity
1104 during neuronal migration. *Neuropharmacology* **32**, 1239-1248 (1993).
1105 83. C. Akazawa, R. Shigemoto, Y. Bessho, S. Nakanishi, N. Mizuno, Differential expression of
1106 five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and
1107 adult rats. *The Journal of comparative neurology* **347**, 150-160 (1994).
1108 84. M. Watanabe, M. Mishina, Y. Inoue, Distinct spatiotemporal expressions of five NMDA
1109 receptor channel subunit mRNAs in the cerebellum. *The Journal of comparative*
1110 *neurology* **343**, 513-519 (1994).
1111 85. K. Tarnok, K. Czondor, M. Jelitai, A. Czirok, K. Schlett, NMDA receptor NR2B subunit
1112 over-expression increases cerebellar granule cell migratory activity. *Journal of*
1113 *neurochemistry* **104**, 818-829 (2008).
1114 86. K. Schlett *et al.*, Long-term NR2B expression in the cerebellum alters granule cell
1115 development and leads to NR2A down-regulation and motor deficits. *Mol Cell Neurosci*
1116 **27**, 215-226 (2004).
1117 87. H. Komuro, P. Rakic, Selective role of N-type calcium channels in neuronal migration.
1118 *Science* **257**, 806-809 (1992).

1119 88. P. Zhou *et al.*, Polarized signaling endosomes coordinate BDNF-induced chemotaxis of
1120 cerebellar precursors. *Neuron* **55**, 53-68 (2007).
1121 89. P. R. Borghesani *et al.*, BDNF stimulates migration of cerebellar granule cells.
1122 *Development* **129**, 1435-1442 (2002).
1123 90. M. Kokubo *et al.*, BDNF-mediated cerebellar granule cell development is impaired in
1124 mice null for CaMKK2 or CaMKIV. *J Neurosci* **29**, 8901-8913 (2009).
1125 91. S. Pons, J. L. Trejo, J. R. Martinez-Morales, E. Marti, Vitronectin regulates Sonic
1126 hedgehog activity during cerebellum development through CREB phosphorylation.
1127 *Development* **128**, 1481-1492 (2001).
1128 92. G. U. Hoglinger *et al.*, The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's
1129 disease. *Proc Natl Acad Sci U S A* **104**, 3585-3590 (2007).
1130 93. K. L. Jordan-Sciutto, L. M. Malaiyandi, R. Bowser, Altered distribution of cell cycle
1131 transcriptional regulators during Alzheimer disease. *Journal of neuropathology and*
1132 *experimental neurology* **61**, 358-367 (2002).
1133 94. H. Osuga *et al.*, Cyclin-dependent kinases as a therapeutic target for stroke. *Proc Natl*
1134 *Acad Sci U S A* **97**, 10254-10259 (2000).
1135 95. G. C. Wong, K. H. Chow, DNA Damage Response-Associated Cell Cycle Re-Entry and
1136 Neuronal Senescence in Brain Aging and Alzheimer's Disease. *J Alzheimers Dis* **94**, S429-
1137 S451 (2023).
1138 96. I. Blumcke, O. D. Wiestler, Gangliogliomas: an intriguing tumor entity associated with
1139 focal epilepsies. *Journal of neuropathology and experimental neurology* **61**, 575-584
1140 (2002).
1141 97. M. J. Hicks, B. Mackay, Comparison of ultrastructural features among neuroblastic
1142 tumors: maturation from neuroblastoma to ganglioneuroma. *Ultrastructural pathology*
1143 **19**, 311-322 (1995).
1144 98. E. Miele *et al.*, The histone methyltransferase EZH2 as a druggable target in SHH
1145 medulloblastoma cancer stem cells. *Oncotarget* **8**, 68557-68570 (2017).
1146 99. I. Alimova *et al.*, Targeting the enhancer of zeste homologue 2 in medulloblastoma.
1147 *International journal of cancer. Journal international du cancer* **131**, 1800-1809 (2012).
1148 100. Y. Cheng *et al.*, NeuroD1 Dictates Tumor Cell Differentiation in Medulloblastoma. *Cell*
1149 *reports* **31**, 107782 (2020).
1150 101. M. Leszczyniecka, T. Roberts, P. Dent, S. Grant, P. B. Fisher, Differentiation therapy of
1151 human cancer: basic science and clinical applications. *Pharmacology & therapeutics* **90**,
1152 105-156 (2001).
1153 102. G. B. Pierce, C. Wallace, Differentiation of malignant to benign cells. *Cancer research* **31**,
1154 127-134 (1971).
1155 103. G. B. Pierce, The cancer cell and its control by the embryo. Rous-Whipple Award lecture.
1156 *The American journal of pathology* **113**, 117-124 (1983).
1157 104. D. Head *et al.*, Effect of aggressive daunomycin therapy on survival in acute
1158 promyelocytic leukemia. *Blood* **86**, 1717-1728 (1995).
1159 105. H. J. Iland *et al.*, All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial
1160 therapy in acute promyelocytic leukemia (APML4). *Blood* **120**, 1570-1580; quiz 1752
1161 (2012).

1162 106. F. Lo-Coco, L. Cicconi, M. Breccia, Current standard treatment of adult acute
1163 promyelocytic leukaemia. *British journal of haematology* **172**, 841-854 (2016).
1164 107. Z. Y. Wang, Z. Chen, Acute promyelocytic leukemia: from highly fatal to highly curable.
1165 *Blood* **111**, 2505-2515 (2008).
1166 108. Q. Chang *et al.*, All-trans-retinoic acid induces cell growth arrest in a human
1167 medulloblastoma cell line. *Journal of neuro-oncology* **84**, 263-267 (2007).
1168 109. J. Liu, L. Guo, Y. Luo, J. W. Li, H. Li, All trans-retinoic acid suppresses in vitro growth and
1169 down-regulates LIF gene expression as well as telomerase activity of human
1170 medulloblastoma cells. *Anticancer research* **20**, 2659-2664 (2000).
1171 110. A. R. Hallahan *et al.*, BMP-2 mediates retinoid-induced apoptosis in medulloblastoma
1172 cells through a paracrine effect. *Nature medicine* **9**, 1033-1038 (2003).
1173 111. S. E. Spiller, S. H. Ditzler, B. J. Pullar, J. M. Olson, Response of preclinical
1174 medulloblastoma models to combination therapy with 13-cis retinoic acid and
1175 suberoylanilide hydroxamic acid (SAHA). *Journal of neuro-oncology* **87**, 133-141 (2008).
1176 112. M. L. Cook Sangar *et al.*, Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival
1177 in Medulloblastoma Patient-Derived Xenograft Mouse Models. *Clinical cancer research :*
1178 *an official journal of the American Association for Cancer Research* **23**, 5802-5813
1179 (2017).
1180 113. D. Van Mater *et al.*, A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric
1181 patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study
1182 (PBTC-042). *Pediatric blood & cancer* **68**, e28879 (2021).
1183 114. V. Dieras *et al.*, Long-term Pooled Safety Analysis of Palbociclib in Combination With
1184 Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. *Journal of the National*
1185 *Cancer Institute* **111**, 419-430 (2019).
1186 115. S. A. Blythe, C. D. Reid, D. S. Kessler, P. S. Klein, Chromatin immunoprecipitation in early
1187 Xenopus laevis embryos. *Dev Dyn* **238**, 1422-1432 (2009).
1188 116. S. Xu, S. Grullon, K. Ge, W. Peng, Spatial clustering for identification of ChIP-enriched
1189 regions (SICER) to map regions of histone methylation patterns in embryonic stem cells.
1190 *Methods in molecular biology* **1150**, 97-111 (2014).
1191 117. J. Feng, T. Liu, Y. Zhang, Using MACS to identify peaks from ChIP-Seq data. *Current*
1192 *protocols in bioinformatics / editoral board, Andreas D. Baxevanis ... [et al.]* **Chapter 2**,
1193 Unit 2 14 (2011).
1194 118. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for
1195 RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).
1196 119. T. Benaglia, D. Chauveau, D. R. Hunter, D. S. Young, mixtools: An R Package for Analyzing
1197 Mixture Models. *Journal of Statistical Software* **32**, 1 - 29 (2009).
1198 120. F. Yue *et al.*, A comparative encyclopedia of DNA elements in the mouse genome.
1199 *Nature* **515**, 355-364 (2014).
1200 121. M. Pertea *et al.*, StringTie enables improved reconstruction of a transcriptome from
1201 RNA-seq reads. *Nature biotechnology* **33**, 290-295 (2015).
1202 122. A. R. Quinlan, I. M. Hall, BEDTools: a flexible suite of utilities for comparing genomic
1203 features. *Bioinformatics* **26**, 841-842 (2010).

1204 123. C. Trapnell, L. Pachter, S. L. Salzberg, TopHat: discovering splice junctions with RNA-Seq.
1205 *Bioinformatics* **25**, 1105-1111 (2009).
1206 124. L. Scrucca, M. Fop, T. B. Murphy, A. E. Raftery, mclust 5: Clustering, Classification and
1207 Density Estimation Using Gaussian Finite Mixture Models. *R J* **8**, 289-317 (2016).
1208 125. I. Diboun, L. Wernisch, C. A. Orengo, M. Koltzenburg, Microarray analysis after RNA
1209 amplification can detect pronounced differences in gene expression using limma. *BMC*
1210 *genomics* **7**, 252 (2006).
1211 126. H. Y. Lee, L. A. Greene, C. A. Mason, M. C. Manzini, Isolation and culture of post-natal
1212 mouse cerebellar granule neuron progenitor cells and neurons. *Journal of visualized*
1213 *experiments : JoVE*, (2009).
1214 127. S. D. Cappell, M. Chung, A. Jaimovich, S. L. Spencer, T. Meyer, Irreversible APC(Cdh1)
1215 Inactivation Underlies the Point of No Return for Cell-Cycle Entry. *Cell* **166**, 167-180
1216 (2016).

1217

1218

**Figure 1**

**A)** Spatial Distribution of Stages in Cerebellar Development (P7)




**B)** Temporal Distribution of Stages in Cerebellar Development




**C)**



**Figure 1: Identifying a high confidence group of genes that increase with GNP differentiation.**

**A)** Schematic representation of the spatial distribution of stages of GNP development represented in the P7 mouse cerebellum. B) Schematic representation of the temporal distribution of the stages of GNP development. Stages represented in the RNASeq data are indicated by vertical bars. Representative sagittal slices of the cerebellum from mice harboring a *Math1-GFP* reporter, injected with EDU (1.5 h, red) and DAPI (blue) at P1, P7, and P14. **C**) A Sankey diagram describes how genes are partitioned in order to identify high confidence differentiation genes. Briefly, genes are segregated by the following steps: 1, excluded genes by non-expression; 2, excluded genes by contamination from non granule neuron lineage identified through scRNAseq; 3, excluded by minimal change in expression during development; 4, segregated genes by the time of minimum and maximum expression (highest P14 to P6 differentiation genes, highest P0-7 proliferation genes, highest at E15 embryonic genes); 5 excluded genes by low statistical confidence; 6, exclude genes that increase prior to P0; 7, separate by fold-change (>2 fold log2 fold change or 1-2 log2 fold change) .

# Figure 2


A)
Enrichment of epigenetic features in differentiation genes / background genes
Background = all genes
Background = expressed genes
-log10 p-value 5 50 100
H3K27me3
H2Aubi119
1.5
1.0
0.5
0.0
-0.5
H3K4me3
Pol2Ser5P
H3K27ac
H3K4me1
ATAC
H3K36me3
RNAseq
MIRA
Ring1b
H2Aubi119
H3K27me3
B)
Number of genes
750
500
250
0
tail 7
tail 3
tail 9
tail 2
tail 10
tail 5
tail 18
tail
bound 440
bound 697
bound 579
bound 619
bound 594
bound 351
bound 133
bound 39
417 (94.8%)
391 (88.9%)
385 (87.5%)
371 (84.3%)
158 (35.9%)
78 (17.7%)
(4.1%)
unbound 339
unbound 86
unbound 198
unbound 165
unbound 192
unbound 425
unbound 648
unbound 745
H3K27me3
H3K4me1
H2Aubi119
H3K4me3
Pol2Ser5P
H3K27ac
Ring1b
MIRA
Chromatin modifications
H3K27me3 binding class
bound
tail
unbound

**Figure 2**: **H3K27me3 modification near the promoter of genes at P7 is associated with genes that increase later with differentiation.**

**A)** Enrichment of chromatin features near promoters of proliferating P7 GNP whose expression increases during differentiation**.** Enrichment is calculated for a given modification as the number of differentiation genes over either all genes (black) or genes expressed at any point during the granule neuron lineage (green). The log2 value of this fraction is then shown on the figure. The p-value is calculated using the hypergeometric test and the p-values are shown as the size of the dot. **B)** A parallel sets diagram that shows correlation between H3K27me3 binding and other modification. The disconnected bar graphs shows the number of genes that are bound or within the long upper tail for each modification. The red colour that spans the bar segments shows the genes that contain the next modification.

**Figure 3**


A)
oEGL
iEGL
ML
Purkinje Cells
IGL
B)
oEGL
iEGL
ML
Purkinje Cells
IGL
C)
oEGL
iEGL
ML
Purkinje Cells
IGL
D)
p27
Normalized p27 mean intensity
oEGL
iEGL
ML
IGL
WT
Ezh2_cKO
E)
Intensity Difference Ezh2 cKO - WT
Micrometers from pial boundary
G)
i) WT
ii) WT
iii) Ezh2 cKO
iv) Ezh2 cKO
I
II
III
IV
V
VI
VII
VIII
IX
X
F)
Micrometers from pial boundary: 19.45
Micrometers from pial boundary: 41.98
p = 1.75e-02
p = 1.01e-02
Normalized p27 mean intensity
WT
Ezh2 cKO
H)
oEGL
iEGL
ML
IGL
genotype
Wt
Ezh2 cKO
Area (mm^2)
p = 0.2
p = 0.34
p = 0.91
p = 0.87
Genotype
I)
iEGL
IGL
p = 0.028
p = 0.013
Relative p27 Intensity
Genotype

**Figure 3: *Ezh2* cKO leads to a depletion of the inner EGL**

**A)** Schematic of granule neuron (GN) development in a P7 cerebellum sagittal slice. Inner external grandule layer (iEGL), outer external granule layer (oEGL); molecular layer (ML), internal granule layer (IGL). **B)** WT and **C)** *Ezh2* cKO 40x confocal micrographs of the deep sulcus between lobule V and VI in the control and in the cKO, showing DAPI (red) and p27 (green; a cell cycle arrest marker in GNPs). In the mutant, the boundary between the inner EGL and the ML and the ML with the IGL is ill-defined. The cyan arrow indicates the position of the inner EGL, there are fewer p27 labeled cells sitting within the EGL. The cellular density is reduced in both the inner EGL and IGL. **D)** Quantification of the boundaries adjacent to the ML in WT and *Ezh2* cKO by collapsing 2D images into 1D line segments**.** The line segments for anti-p27 immunofluorescence span from the pial boundary to the IGL and show a hump of high average fluorescence at the inner EGL and the IGL. In the *Ezh2* cKO the iEGL p27 signal extends further into the ML then in the WT. The blue arrows show the approximate position of the transition between the iEGL and the ML. E) The average fluorescence intensity difference between mutant (n = 7) and WT (n = 4) shows where along the line segment from the pia to the IGL is the *Ezh2* cKO most different from the WT. Positive values are associated with p27 value being higher in the *Ezh2* cKO and is highest at the boundary of the inner EGL and the ML and to a lesser extent at the boundary between the ML and IGL. The WT shows higher signal within the inner EGL itself where the values of E are negative. **F)** Quantification of each line segment at the point where the differences between *Ezh2* cKO and WT are largest as indicated by the hashed lines seen in panel D and E. The left panel shows quantification at position where the WT had had more P27 staining then to the *Ezh2* cKO and the right panel shows the opposite.

The distribution of the values at the 2 positions in right and left panel for the 266 WT and 315 *Ezh2* cKO line segments was shown as a violin plot (a histogram that is mirrored). The dots correspond to individual mice, with multiple slides analyzed for each mouse. P-values are calculated using a T-test showing a significant increase of P27 labeling within the boundary of the EGL and ML. G) Segmentation into inner and outer EGL, ML, IGL and deep white matter using panoramic images of the entire cerebellum, labeled with DAPI, P27, NeuN. Anti-p27 over the entire P7 cerebellar section, for WT i) and *Ezh2* cKO ii). **H)** Quantification of the area for each layer in WT and *Ezh2* cKO shows no significant difference, indicating the overall structure of the cerebellum is not dramatically altered and the phenotype is limited to the early migration out of the inner EGL. **I)** Quantification of the anti-p27 fluorescence intensity by layer shows a decrease in the fluorescence in *Ezh2* cKO versus WT, for the inner EGL (p-value 0.028, t-test) and IGL (p-value 0.013, t-test). The decrease in p27 abundance suggests that the total number of neurons within the inner EGL and the IGL density of cells within those areas is reduced.

**Figure 4**


A)
B)
WT
MAP2
DAPI
C)
D)
Ezh2
CKO
MAP2
DAPI
E)
p=0.007
Mean process lenght
60
40
20
0
Ezh2 cKO
WT
Ezh2
F)
p=0.019
p=0.005
p=0.276
p=0.001
p=0.013
p=0.009
WT
Ezh2 cKO
Mean Fraction of Cells
0.4
0.3
0.2
0.1
0.0
none
<= 5
<= 10
<= 50
<= 100
> 100
Neurite length Group

**Figure 4**: ***Ezh2* cKO leads to premature process extension and NeuN expression**.

GNPs cultured for 24 in Shh, were labeled with DAPI (nucleus) and for MAP2 (neuronal processes) (**A,C**), then segmented with Neuronctyo 2 (**B,D**). Segmented images showed increased process extension in *Ezh2* cKO (**D** for cKO versus WT in **B**). **F**) Mean process length comparison between *Ezh2* cKO and WT shows cells in *Ezh2* cKO mice had significantly longer processes (n = 5). **E**) Quantification of the number of cells with no process, a process less than 5, 10, 50, 100 pixels, or greater then 100 pixels, showed a significant increase in the number of processes longer then 50 pixels. P-value determined by T-test.

**Figure 5**


A)
Cbx7
Pcgf5
Phf19
Cbx6
Mll2
Aebp2
Ezh1
Phf1
Suz12
Jarid2
Rbbp4
Rbbp7
Mtf2
Ash2l
Hdac2
Ezh2
Protein Complex
PRC2
PRC1
PRC1.1
PRC1.3.5
PRC1.6
JMJD3 complex
UTX complex
MLLL complex
log2 Fold Change
Rank by Log2 Fold Change (FC)


B)
Ezh2
E15
P1
P7
P0
P7
P14
P12
P18
P21
P56
NeuroD1-TRAP
RNAseq
log2 fold change


C)
oEGL
iEGL
ML
Purkinje Cells
IGL
C'
C''
C'''
Ezh2
DAPI
NeuN


D)
Dissociated GNPs
Culture for 6h
Culture for 24h
Image and quantify
6h
24h
cell_number 1000 2000 3000
Ezh2 Relative Fluorescence
High Math1>GFP
Low Math1>GFP
High Math1>GFP
Low Math1>GFP

**Figure 5**: **Transcriptional regulation of known H3K27me3 effector protein complexes during granule neuron (GN) development.**

**A)** Rank order plot of genes that change expression during GN development shows *Ezh2* as the gene with the largest decrease in RNA abundance. The y-axis indicates the combined fold change for both datasets. **B)** RNA abundance over time for *Ezh2*. **C**) Schematic of granule neuron (GN) development in a P7 cerebellum sagittal slice. A P7 cerebellar slice stained with Anti-Ezh2 (left), DAPI (middle), and NeuN (right) shows reduced Ezh2 staining intensity in the postmitotic cells of the iEGL and EGL. **D)** Schematic of GNP culture without Shh, which causes GNPs to immediately exit cell cycle. Ezh2 protein abundance was measured after 6 h and 24, splitting cells into proliferating (high Math1>GFP) cells and non-proliferating (low Math1>GFP) cells (n=6). The decrease in Ezh2 shortly after cell cycle suggests that the decrease in Ezh2 is linked to cell cycle exit but does not show a causal relationship.

**Figure 6**


A)
Hoxa10
Wnt7a
Cbx7
Phyhip
Hhx9
St8sia5
Unc5b
Ablim1
Hr
Gabra6
MB H3K27me3
GNP H3K27me3
B)
Hr
Cbx7
Unc5b
Gabra6
MB transcript per million
GNP transcript per million
H3K27me3 ChIPseq
GNP and MB
GNP only
MB only
unbound
GNP higher expression
unchanged
MB higher expression
RNAseq differential expression
H3K27me3 modification in both GNP and MB: 336
C)
bound 447
bound 406
high in GNP 321
high in MB 62
differentiation 786
unbound 339
unbound 380
unchanged 403
1a GNP and MB H3K27me3 bound RNA same or higher in GNP 315
1b RNA higher in MB 21
2 H3K27me3 only in GNP 74
3 H3K27me3 only in MB 68
4 no H3K27me3 269
5 other 39
All differentiation genes
GNP H3K27me3 ChIPseq
MB H3K27me3 ChIPseq
Differential expression GNP vs MB
Final classifcation

**Figure 6**: **In medulloblastoma cells GNP differentiation genes are transcriptionally repressed and H3K27me3 modified.**

**A)** H3K27me3 quantified over the promoters of GNP differentiation genes in GNPs (x-axis) and MB (y-axis). Genes are color-coded based upon H3K27me3-marked versus not marked in GNP and MB. Genes whose promoters show more H3K27me3 modification in GNP are shown in red, while those higher in MB are blue and those modified in both are purple. Duller colors (dark tones) were used if higher relative expression in MB than in GNPs. Higher saturation colors indicate gene expressed relatively higher in GNPs than in MB. The colour legend is seen bellow panel A. **B)** Transcript levels of differentiation genes in P7 GNPs, x-axis) versus in *Ptch1*$^{+/-}$ derived MB cells (y-axis). Colors are inherited from panel A with dark tones used for genes in MB (2 fold higher expression and adjusted p-value <0.05) and high saturation colours when higher expression in GNPs. **C)** Sankey diagram showing how the H3K27me3 modified differentiation genes are expressed in MB. The second column shows the differentiation genes in GNP separated by H3K27me3 modification. The third column compares MB H3K27me3 ChIP, showing of 447 H3K27me3 modified GNP differentiation genes, 336 (75%) of those genes are also H3K27me3 modified in MB. The fourth column shows differential expression between P7 GNPs and MB. Even when the H3K27me3 is not present in MB cells only 8% of the differentiation genes show an increase in expression in MB compared to P7 GNPs. The fifth column shows the final classification**.**

**Figure 7**


A)
Cavalli et al SHH MB class
SHH_alpha
SHH_beta
SHH_delta
SHH_gamma
EZH2 transcript group
EZH2 high
EZH2 low
EZH2 mid
number of tumors
EZH2 RNA abundance
B)
CACNA1A
ABLIM1
GABRD
CBX7
PHYHIP
GABRA6
SLC12A5
Average RNA Abundance for EZH2 Low Tumors
Average RNA Abundance for EZH2 High Tumors
EZH2 transcript group
High when EZH2 low
Low when EZH2 low
other
C)
enrichment = |log2(n_gene(GNP_group∩EZH2_low) / n_gene(GNP_group∩EZH2_high))|
GNP expression time course group
unchanged
Proliferation genes 1-2 log2FC
Proliferation genes >2 log2FC
Differentiation genes 1-2 log2FC
Differentiation genes >2 log2FC
Number of genes in EZH2 MB differential expression groups
Log2 fold enrichment
Differential expression
Genes increased when EZH2 low
Genes increased when EZH2 high
-log10 p-val
D)
Survival probability
EZH2 transcript group
EZH2=high
EZH2=low
p = 0.019
53 44 39 36 34
55 50 50 48 46
Time in years

**Figure 7: Human SHH MBs with High EZH2 are associated with worse outcome and show lower expression of GNP differentiation genes**.

**A)** Labeled dot histogram of *EZH2* transcript abundance from 223 human SHH MB with the top (orange) and bottom (brown) 30% labeled. Each human tumor is represented as a dot with the symbols reflecting the most recent SHH MB classification (*9*). Note the high number of patients with gamma-class SHH MB with low EZH2 expression. These patients are infants with a typically good prognosis. **B)** Comparison of average gene expression between the human MB samples from the 30% highest (x-axis) and lowest EZH2 (y-axis) expressing tumours. The color labels show more highly expressed genes that are 1.5 fold higher (adjusted $p < 0.05$) in tumours that were low in EZH2 were labelled orange, while those that are higher in *EZH2* high tumours are brown. The GNP differentiation genes (red) show considerable overlap with the genes highest in EZH2 low tumours (orange), while the GNP proliferation genes (green) show overlap with the genes that are highest in EZH2 high tumours (brown). **C)** Quantification of the extensive overlap between GNP differentiation genes and genes highly expressed in EZH2 low human MB tumours. The categories of genes based on the GNP time course (y-axis) are quantified using a bar graph that shows the intersection of genes for each GNP group to either genes that are highly expressed when Ezh2 is low ($EZH2_{low}$) or genes that are highly expressed when Ezh2 is high ($EZH2_{high}$). Enrichment is calculated as the number of GNP group genes that intersect ($\cap$) with $EZH2_{low}$ genes over the number that intersect with $EZH2_{high}$ genes as described in the equation. The p-value is determined by the hypergeometric test. **D)** Kaplan-Meyer curves show a significant 10 year survival difference for SHH MB patients with high versus low EZH2 transcript.

**Figure 8**


A)
Dissociate MB spheres
Culture with drugs 72h
Image and quantify
Atoh1 +p27 (C/D)
pRB +NeuN (B)
B)
Palbociclib 0 uM
Palbociclib 1 uM
p < 0.001 / p < 0.001
p < 0.001 / p < 0.001
p = 0.76 / p = 0.86
p = 0.004 / p < 0.001
p = 0.027 / p < 0.001
p = 0.72 / p = 0.8
Fraction of cells
Concentration of UNC1999 (uM)
Cell classification
G0
G0 high NeuN
G1/2
Cell Line
MB55
MB56
p53_null
C)
Wash out drug
Dissociate MB spheres
Culture with drugs 72h
Culture without drugs 24h
Image and quantify
D)
Palbociclib 1uM
Palbociclib 1uM + UNC1999 5uM
pRB
NeuN
phalloidin
DAPI
E )
Palbociclib 1 uM
p = 0.0092 p < 0.001
p = 0.006 p < 0.001
p = 0.98 p = 0.52
Fraction of cells
UNC1999 (uM), Ezh2 inhibitor
Cell classification
G0
G0 high NeuN
G1/2

**Figure 8: Treatment of MB cells with Ezh2 and CDK4/6 inhibitors leads to differentiation.**

**A)** Schematic of treatment and imaging protocol. MB cells were treated using the Ezh2 inhibitor UNC1999 with or without the CDK4/6 inhibitor palbociclib. **B)** Quantification of immunofluorescence in treated MB cells (n = 16), derived from *Ptch1*$^{+/-}$ mice, stained for NeuN, pRb (Ser807/811) and DAPI to categorize the cells as in G1/2 (green), G0 (yellow) and differentiating (G0 with high NeuN (red)). Note an increase in fraction of cells scored as differentiating with combined Palbociclib and UNC1999 treatment. **C)** Schematic of treatments with inhibitors followed by drug wash out. **D)** Immunofluorescence images of fields of MB cells stained for NeuN (red), pRb (green), DAPI (blue) and phalloidin (grey) after treatment for 72h with 1 uM Palbociclib (i-iii) combined with 1 uM Palbociclib or 5 uM UNC1999 (iv-vi) followed by washout as per C. Dashed boxes in i and iv show regions enlarged in ii and v respectively, with the individual colour channels shown in separate panes. Note fewer pRB positive cells with UNC1999 and Palbociclib (iv) than with Palbociclib alone (i). **E)** Quantification of fractions of cells in G0, G1/2, and G0 and differentiating as described in B (n = 8). Note that the MB cells treated with both UNC1999 and Palbociclib showed persistent cell cycle exit even after washout. P-values in B and E calculated using ANOVA with post-hoc Tukey test.